Corrected on Mar 8, 2019.

Source: the publisher, via Crossref · checked Oct 19, 2026 · Read the notice

Anakinra Therapy for Non-cancer Inflammatory Diseases

Giulio Cavalli, Charles A. Dinarello

Frontiers in Pharmacology · 2018 · Review · CC BY

doi:10.3389/fphar.2018.01157

Abstract

Interleukin-1 (IL-1) is the prototypic inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines and chemokines. IL-1α is constitutively present in endothelial and epithelial cells whereas IL-1β is inducible in myeloid cells and released following cleavage by caspase 1. Over the past 30 years, IL-1-mediated inflammation has been established in a broad spectrum of diseases, ranging from rare autoinflammatory diseases to common conditions such as gout and rheumatoid arthritis, type 2 diabetes, atherosclerosis, and acute myocardial infarction. Blocking IL 1 entered the clinical arena with anakinra, the recombinant form of the naturally occurring IL 1 Receptor antagonist (IL 1Ra); IL 1Ra prevents the binding of IL 1α as well as IL 1β to IL 1R1. Quenching IL 1-mediated inflammation prevents the detrimental consequences of tissue damage and organ dysfunction. Although anakinra is presently approved for the treatment of rheumatoid arthritis and cryopyrin-associated periodic syndromes, off-label use of anakinra far exceeds its approved indications. Dosing of 100 mg of anakinra subcutaneously provides clinically evident benefits within days and for some diseases, anakinra has been used daily for over 12 years. Compared to other biologics, anakinra has an unparalleled record of safety and opportunistic infections, particularly Mycobacterium tuberculosis are rare, even in populations at risk for reactivation of latent infections. Because of this excellent safety profile and relative short duration of action, anakinra can also be used as a diagnostic tool for undefined diseases mediated by IL 1. Although anakinra is presently in clinical trials to treat cancer, this review focuses on anakinra treatment of acute as well as chronic inflammatory diseases.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Historical Background of IL-1 and IL-1Ra

1The history of interleukin 1 (IL-1) dates back to the purification of the endogenous fever-producing protein called leukocytic pyrogen, as reviewed in. During the purification of the leukocytic pyrogen, two fever-inducing proteins were observed with different molecular weights and distinct isoelectric points. Specifically, human blood monocytes produced both a high (35 kDa) as well as a low (15 kDa) molecular weight leukocytic pyrogen, with two distinct isoelectric points at 5.1 and 6.8, respectively. also reported two leukocytic pyrogens, with isoelectric focusing points of 5.1 and 7.0 from rabbit cells. The specific biologic activity of purified human leukocytic pyrogen was first reported in 1977 as the induction of fever in rabbits at 10 ng/kg. Thus, the in vivo potency of IL-1 was established in 1977 and later confirmed in animals and humans with recombinant IL-1β. In 1979, based on the ability of purified human leukocytic pyrogen to enhance T-cell proliferation in response to antigen recognition, the name “leukocytic pyrogen,” or “lymphocyte activation factor” was replaced with the current nomenclature “IL-1”. The 1984 cDNA cloning of IL-1β in humans and IL-1α in mice univocally established that there were in fact two distinct genes coding for IL-1. Looking back today, the higher molecular weight fever-producing molecule was likely the IL-1α precursor, which unlike the IL-1β precursor is biologically active without processing. In contrast, the IL-1β precursor requires processing and proteolytic cleavage in order to generate the lower molecular weight and biologically active IL-1β.

2Interleukin-1β exerts clinically marked pro-inflammatory effects at very low concentrations and correlations of circulating levels of IL-1β with disease severity is often not possible due to the limited sensitivity of immunoassays. Instead, human plasma has been assayed for IL-1 bioactivity by enhancement of PHA-induced proliferation of mouse thymocytes in vitro. This assay was reliable in that indirect readouts of IL-1 activity were found in plasma samples of subjects with endotoxemia and in women during the menstrual cycle. The bioassay for IL-1 required chromatographic separation of each plasma sample in order to remove inhibitory proteins present in the plasma. Specifically, plasma from healthy human subjects was obtained before and after intravenous inoculum of a low dose of endotoxin. Before the administration of the endotoxin, the plasma fractions had no effect on thymocyte proliferation; however, 4 h after endotoxin administration, at the peak of the fever, fractions suppressed thymocyte proliferation. Thus, there was an endotoxin-inducible suppressor “factor” specifically inhibiting IL-1-mediated thymocyte proliferation in the circulation.

3Subsequent to this observation, others reported the presence of a “specific” inhibitor of IL-1 bioactivity in supernatants of human monocytes and in the serum and urine of children with systemic juvenile arthritis. In 1987, this “IL-1 inhibitor” isolated from the urine was shown to prevent binding of IL-1 to cells, thus providing evidence for its mechanism of action. The IL-1 inhibitor was purified in 1990; the cDNA sequence first reported that same year and the term IL-1 receptor antagonist (IL-1Ra) was used for the first time in that report. Following the cDNA cloning of IL-1Ra, a radioimmunoassay for IL-1Ra was developed and used to assay the plasma samples from subjects during experimental endotoxemia. Endogenous IL-1Ra is found at very low levels in the circulation of healthy subjects (less than 200 rpg/mL), but levels steeply rise to a mean level of 1435 pg/mL 2 h after the infusion of endotoxin, and to top levels of 6400 pg/mL at the peak of the fever 4 h after infusion of endotoxin. Of note, IL-1β levels reached peak levels of only 20 pg/mL in the same samples. In that study, the kinetics of IL-1Ra matched the induction of the specific suppressor of IL-1-mediated thymocyte proliferation reported during experimental endotoxemia in 1981. In addition, the study also revealed that there was a molar excess of at least 100-fold IL-1Ra over IL-1β. It was not until the reports of subjects with a genetic deletion of IL-1Ra that the critical function of this endogenous inhibitor, which naturally suppresses IL-1 mediated inflammation, was fully revealed.

4As stated in our review, in 1981 we described a circulating suppressor factor from humans during experimental endotoxemia as assayed for specific inhibition of IL-1 activity in vitro. We believe this circulating suppressor factor was the first description of IL-1Ra, and we confirmed our findings in a report published in Lancet in 1991 using a specific radioimmunoassay for IL-1Ra. However, in 1984, there was documentation from the group of Jean-Michel Dayer describing a specific inhibitor of IL-1 activity isolated from the urine of patients with monoblastic leukemia. This was an essential contribution to the history of the discovery of the antagonist. In 1985, there was another report from the Dayer laboratory “Collagenase- and PGE2-Stimulating Activity (Interleukin-1-Like) and Inhibitor in Urine from a Patient with Monocytic Leukemia,” as published in Progress in Leukocyte Biology, vol. 2 (New York, NY: Alan R. Liss, 1985 p. 429). These reports were followed by another publication in the Journal of Clinical Investigation. As stated in our Review, “the IL-1 inhibitor” isolated from the urine was shown to prevent binding of IL-1 to cells, thus providing for the first time evidence for its mechanism of action. Because of the widespread and beneficial use of anakinra (the recombinant form of the nature IL-1Ra) to treat human diseases, the contributions of Jean-Michel Dayer as well as those of William Arend are paramount.

Synthesis and Release of IL-1β

5Interleukin-1β is not produced or detectable with standard immunoassays in healthy tissues; rather, IL-1β is mainly produced by inflammatory cells of the myeloid compartment: blood monocytes, tissue macrophages, and dendritic cells. Figure 1 summarizes the mechanisms of IL-1 activation and signaling.

6Production is stimulated by exogenous Toll-like receptor (TLR) agonists or by endogenous cytokines such as TNFα. IL-1α and IL-1β induce themselves. This self-sustained induction of IL-1 is a key mechanism of autoinflammation. In order to prevent unwanted release and runaway inflammation, IL-1β is synthesized as an inactive precursor, whose activation is contingent on proteolytic cleavage by caspase-1, an intracellular cysteine protease. In turn, activation of caspase-1 requires the oligomerization and assembly of the “inflammasome,” a complex of intracellular proteins. Once activated, caspase-1 cleaves the N-terminal amino acid of the inactive IL-1β precursor, thus enabling the release of the processed, biologically active form of this cytokine. Assembly and activation of the inflammasome thereby represents a critical safety mechanism preventing deregulated release of IL-1β. Unrestricted activation of caspase-1 and secretion of IL-1β lead to systemic and multi-organ sterile inflammation, which characterizes autoinflammatory diseases.

Anakinra Reveals the Nature of Autoinflammatory Disorders

7The term IL-1 is often used without distinguishing between the two gene products, IL-1α and IL-1β. This is because both cytokines bind to the same signaling receptor, the IL-1 receptor 1 (IL-1R1), and hence there is no significant difference between the biological activities of either cytokine. IL-1Ra, also an endogenous member of the IL-1 family, binds to the IL-1R1 and therefore blocks the activity of both IL-1α and IL-1β. A recombinant form of IL-1Ra (anakinra) is used to treat a broad variety of diseases, ranging from common conditions such as rheumatoid arthritis (RA), gout, and idiopathic pericarditis, to rare hereditary diseases. Specific mutations in diseases such as familial Mediterranean fever (FMF) and cryopyrin-associated periodic syndrome (CAPS) result in deregulated release of active IL-1β, which is clinically manifested as periodic fevers with systemic and local inflammation. These diseases do not involve T-lymphocytes, which characteristically represent the effector cells of every autoimmune disease, nor autoantibodies. Therefore, these diseases are not considered autoimmune diseases, but rather termed “autoinflammatory” syndromes. In autoinflammatory diseases, the effector cell is a myeloid cell, characteristically a monocyte or macrophage. The central role of IL-1 in the pathogenesis of autoinflammation is well established. Monocytes from patients with autoinflammatory diseases release more IL-1β, but not TNFα, compared to healthy persons.

8Autoinflammatory diseases can be regarded as a “natural experiment”, which reveals the clinical and pathologic consequences of deregulated IL-1-mediated inflammation in humans. Lessons from autoinflammatory diseases extend and apply beyond this group of rare conditions: deregulated activation of the myeloid compartment and IL-1 also mediate several common diseases, which can also be classified as autoinflammatory disorders (i.e., gout, pericarditis), or at least include autoinflammation as part of disease pathogenesis (i.e., heart failure, diabetes, myocarditis;;; ). Because of the safety and rapid onset of action, IL-1 inhibition with anakinra can be used as a diagnostic as well as a treatment tool for patients with undefined signs or symptoms of autoinflammation. Figure 2 illustrates the broad variety of organ manifestations of IL-1-mediated inflammation, which can be treated with anakinra.

Autoinflammatory Diseases

9Autoinflammatory diseases are a spectrum of hereditary or multifactorial conditions variably manifested with clinical and hematologic features of IL-1-mediated inflammation: these include fever, fatigue, myalgia, arthralgia, arthritis, serositis, gastrointestinal involvement, skin rashes, and multi-organ involvement, often accompanied by neutrophilia and elevated inflammatory markers. Most autoinflammatory diseases occur in recurrent flares. In some autoinflammatory diseases, causative mutations resulting in deregulated release of active IL-1 have been identified. However, in other autoinflammatory diseases, a specific mutation to account for excessive IL-1 activity has not yet been determined; in some cases, defects in regulatory molecules counteracting the biologic activity of IL-1 can be determined, or postulated. Regardless of the underlying mechanisms, disease manifestations are characteristically controlled by IL-1 blockade with anakinra; as different pharmacokinetics result in more prolonged duration of action, neutralizing antibodies directed against IL-1β (canakinumab) represent an alternative in patients enduring frequent disease flares. The efficacy of anakinra in the treatment of these conditions is discussed below; more detailed lists of hereditary as well as non-hereditary inflammatory diseases responsive to anakinra treatment are provided in Tables 1, 2.

Cryopyrin-Associated Periodic Syndromes (CAPS)

10The term “CAPS” encompasses a spectrum of three hereditary diseases: familial cold autoinflammatory syndrome (FCAS), Muckle–Wells syndrome (MWS), and neonatal onset multi-inflammatory diseases (NOMID). The clinical phenotypes of FCAS, MWS, and NOMID are characterized by escalating severity, ranging from self-limited episodes of fever, myalgia, and skin rash (FCAS), to chronic systemic and organ-specific inflammation with major complications (NOMID). The pathologic hallmark of CAPS is the presence of activating mutations in the NLRP3 inflammasome, which result in induction of caspase 1 and deregulated release of IL-1β. Anakinra, as well as other IL-1-blocking agents, is dramatically effective in the treatment of CAPS (reviewed in ).

Familial Mediterranean Fever (FMF) and Amyloidosis

11Familial Mediterranean fever is a prototypical autoinflammatory disease characterized by recurrent bouts of fever, rash, and serositis, which are typically self-limited in 3–5 days. The disease is autosomal recessive, and determined by mutations in the MEFV gene, encoding for pyrin, a protein involved in inflammasome formation, activation of caspase 1, and release of active IL-1β. Colchicine is the cornerstone of treatment for FMF, but is ineffective in some patients. Patients refractory to conventional treatment are successfully treated with anakinra.

12Interleukin-1 induces serum amyloid A (SAA), which is thereby commonly elevated in several chronic inflammatory diseases. Progressive deposition of amyloid fibrils in tissues results in amyloidosis, a condition leading to severe organ dysfunction, including lethal kidney or heart failure, which are major causes of death in untreated FMF and CAPS. However, effective dampening of chronic inflammation with IL-1 blockers prevents progression to amyloidosis and organ failure. Intriguingly, amyloid deposition leading to organ dysfunction is also a feature of other, multifactorial conditions in which IL-1 has emerged as a pivotal pathologic mediator: amyloidosis of insulin-producing islets and brain characterizes T2D and Alzheimer disease, respectively. In both conditions, IL-1 blockade may represent a suitable therapeutic strategy to hinder disease progression.

TNF-Receptor Associated Periodic Syndrome (TRAPS)

13TNF-receptor associated periodic syndrome (TRAPS) is an autosomal dominant disease caused by mutations in TNF-receptor type 1, and clinically manifested as recurrent flares of fever, rash, and serositis. A deficiency of soluble TNFα receptors, which neutralizes circulating TNFα, was postulated. Nevertheless, clinical response to TNFα inhibition is only partial, and even absent in many patients. Current understanding rather postulates a deficit in membrane translocation of TNF-receptor type 1, which leads to an unfolded protein response, cellular stress, and consequent release of IL-1β. This view is also substantiated by clinical efficacy of anakinra, even in refractory cases.

Hyper-IgD Syndrome (HIDS)

14Also known as mevalonate kinase deficiency, Hyper-IgD syndrome (HIDS) is an autosomal recessive autoinflammatory disorder characterized by recurrent fever, myalgia, skin rash, and lymphadenopathy. Episodes usually last 4–6 days and can be triggered by infections. Multiple intracellular pathways link mevalonate kinase deficiency with deregulated release of IL-1 production. Consistently, IL-1 inhibitors effectively reduce the frequency and severity of the attacks of HIDS.

Adult Onset Still’s Disease (AOSD) and Systemic Onset Juvenile Idiopathic Arthritis (SOJIA)

15Adult onset Still’s disease (AOSD) is a rare, systemic inflammatory syndrome characterized by arthritis, fever, rash, multi-organ inflammation, and strikingly elevated serum inflammatory indexes, particularly ferritin. Consistent with observations that the NLRP3 inflammasome is highly expressed and activated in AOSD, IL-1β blockade, even with anakinra as monotherapy, represents the mainstay of biologic treatment and effectively controls disease manifestations.

16Rather than being distinct clinical entities, SOJIA and AOSD are considered different manifestations of the same disease, occurring in infancy and adulthood, respectively. The efficacy of anakinra in SOJIA is thereby not unexpected, even in patients refractory to treatment with steroids, methotrexate, or TNFα blockers. Both in AOSD and SOJIA, two distinct clinical phenotypes can be identified. One is characterized by rampant systemic inflammation with neutrophilia and elevated acute phase proteins, and by a lower number of inflamed joints: this form is dramatically and characteristically responsive to IL-1 blockade. On the other hand, a clinical phenotype characterized by more severe arthritis and limited systemic inflammation may not respond as brilliantly to IL-1 inhibition.

17Of note, treatment of SOJIA poses challenges beyond the mere achievement of disease control, related to the problematic use of immunosuppressive therapies in a pediatric population. For instance, steroid treatment is associated with growth retardation. In this scenario, IL-1 inhibition may be particularly advantageous, as treatment with anakinra or canakinumab results in reduced glucocorticoid dosing and catch-up growth. A prospective study evaluated anakinra (2 mg/kg) as a first-line drug in 20 children with new-onset SOJIA, and documented a near complete clinical response within 3 months of treatment initiation, which was sustained at 32 months of follow-up and allowed most patients to discontinue treatment.

Schnitzler Syndrome (SchS)

18Schnitzler syndrome (SchS) is characterized by chronic urticarial, fever, and development of hematopoietic malignancies, particularly Waldenström macroglobulinemia. The SchS International Registry reports nearly 100% efficacy with anakinra treatment, which leads to clinical improvement within hours and remission within days. Remission upon treatment is durable, but disease flares may occur at discontinuation. The efficacy of anakinra is SchS is so distinctive that diagnosis should be reconsidered in the event of treatment failure. Canakinumab is also highly effective in SchS. Of note, a recent study reported that some patients with SchS have myeloid-lineage restricted somatic mosaicism for mutations in NLRP3, which is associated with increased IL-1 activity in monocytes. This phenomenon likely explains the late onset of disease in some patients.

Anakinra for the Heart

19The central role of IL-1-mediated inflammation is established in the pathogenesis of atherosclerosis, ischemia-reperfusion injury, cardiac remodeling, and myocardial infarction. The beneficial effects of IL-1 blockade with anakinra in heart disease are discussed hereby, and summarized in Table 3.

Atherosclerosis

20Chronic inflammation is central to the pathogenesis of atherosclerosis, and IL-1 specifically promotes the formation, growth, and rupture of vascular atherosclerotic plaques, which account for ischemic cardiovascular complications. Both IL-1β and IL-1α are highly expressed in atherosclerotic lesions, and promote recruitment of leukocytes by inducing endothelial cells to express adhesion molecules; in addition, IL-1 impairs vasodilation while inducing oxidative stress and pro-coagulant mediators. Experimental pre-clinical evidence shows that many of these effects can be reversed by IL-1β inhibition, thus pointing at selective pharmacological blockade as a suitable treatment strategy to dampen progression of atherosclerotic lesions. Although the ability of anakinra or other IL-1β blocking drugs to prevent progression of atherosclerosis in humans has not been specifically studied, IL-1 inhibition with anakinra and canakinumab proved beneficial in the treatment of major clinical complications of atherosclerosis, such as acute myocardial infarction and ischemic cardiovascular disease, as detailed in the following sections of this review.

Acute Myocardial Infarction

21The first studies of anakinra in acute ischemic heart disease involved patients who had suffered a ST-elevated myocardial infarction (STEMI;, ). In these studies, anakinra 100 mg daily was administered subcutaneously for 2 weeks, following stent placement and in addition to optimal standard of care. Seventy-two hours after the acute event, despite optimal standard of care, inflammation develops due to myocardial ischemia; CRP reaches peak levels, which correlate with the size of the infarcted area. Anakinra treatment resulted in a significant reduction in CRP levels, thus reducing the progressive inflammatory response and myocardial damage. Infiltration of neutrophils and monocytes into the area surrounding the ischemic tissue contributes to further damage, which is significantly reduced by anakinra treatment in animal studies. Twelve weeks following myocardial infarction, heart function of patients was evaluated as residual left ventricular ejection fraction. Compared to the placebo-treated group, anakinra-treated patients exhibited improved functional status, but did not reach statistical significance. A second trial was performed with 30 patients. Again, anakinra significantly reduced CRP levels 72 h after myocardial infarction; after 10–14 weeks, this reduction in CRP correlated with a reduction in left ventricular end-systolic volume. Patients treated with anakinra exhibited an overall reduction in the development of heart failure (New York Heart Association Grade III and IV) compared to placebo-treated patients.

22Subsequent studies confirmed that anakinra treatment effectively dampens inflammation associated with myocardial infarction. Anakinra treatment was started after standard of care for the acute event and protracted for 14 days in 182 patients with non-STEMI myocardial infarction. For 7 days following the acute event, a significant reduction in CPR was observed in patients receiving anakinra compared to placebo (21 compared to 43 mg day/L); levels rose again 16 days after cessation of anakinra.

23In the massive Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), 10,061 patients with prior myocardial infarction and evidence of systemic inflammation as determined by elevated serum CRP were randomized to receive either placebo or canakinumab (50, 150, or 300 mg every 3 months). At 48 months, patients treated with canakinumab 150 mg exhibited a 15% reduction in the primary endpoint of recurrent non-fatal myocardial infarction and non-fatal stroke, or cardiovascular death, as well as reduced need for coronary revascularization, compared to placebo. These definitive results indicate that IL-1β blockade with canakinumab in patients with atherosclerotic cardiovascular disease can prevent recurrent cardiovascular events. Of note, this benefit was closely related to suppression of inflammation, as patients exhibiting the greatest reduction in CRP had improved survival upon treatment.

Heart Failure

24Several years ago, ex vivo studies with human atrial heart strips revealed that IL-1β suppresses cardiac contractility, even at picomolar concentrations. In recent years, various studies examined the effects of anakinra on heart failure with poor exercise tolerance and signs of systemic inflammation. For example, mice treated with a single dose of recombinant human IL-1β have a 76% reduction in response to isoproterenol and a 32% reduction in left ventricular function. In a clinical trial, seven patients with heart failure and markers of systemic inflammation despite standard of care treatment received 100 mg of anakinra daily for 14 days. Compared to baseline, treatment with anakinra was associated with a statistically significant improvement in oxygen consumption, a marker of exercise capability. This study first established a role for anakinra treatment in patients with refractory heart failure.

25Besides impaired left ventricular contractility, heart failure with preserved ejection fraction can also occur and be associated with reduced exercise tolerance. When patients with this condition were treated with anakinra 100 mg daily for 14 days in a double-blind, randomized, placebo controlled study, patients receiving treatment exhibited a significant increase in oxygen consumption of 1.2 mL/kg/min and a concomitant 74% reduction in CRP.

26Patients with acute, decompensated heart failure often exhibit signs of systemic inflammation. Thirty patients with acute decompensated heart failure, ejection fraction less than 40%, and elevated CRP were randomized to receive either anakinra or placebo. Upon entering the trial, patients received either 100 mg anakinra or placebo twice daily for 3 days followed by 11 days of once daily dosing. Three days into the trial, CRP decreased by 61% in the anakinra group compared to the placebo-treated group. Although the study was not powered to determine a clinical benefit, it showed that IL-1β inhibition with IL-1 receptor blockade reduced the systemic inflammation associated with acute heart failure.

27In all these trials on heart failure, patients received anakinra for only 14 days. Although clinical and objective data indicate a functional improvement as well as reduced inflammation already with short-term treatment, it is likely that a prolonged course of anakinra would result in a more marked benefit. For example, patients hospitalized with an episode of acute decompensated heart failure are at high risk for repeated hospitalizations due to recurrent episodes. Therefore, a trial was conducted comparing two different treatment durations (2 versus 12 weeks) of anakinra 100 mg daily in patients discharged from the hospital following an episode of acute decompensated heart failure. In this study, patients treated with 12 weeks of anakinra had reduced hospital readmission rates and improved aerobic capacity, oxygen consumption, and quality of life compared to patients receiving either placebo or 2 weeks of anakinra. Of note, patients receiving anakinra for RA exhibited improved cardiac contractility, even within 3 h of a single administration.

Idiopathic Recurrent Pericarditis

28Pericarditis is an autoinflammatory manifestation, often encountered as part of the clinical spectrum of inherited autoinflammatory disorders such as TRAPS, FMF, and CAPS, and successfully treated with anakinra. Patients with AOSD also can have bouts of pericarditis and respond to anakinra.

29However, inflammation of pericardium can occur as an isolated, recurrent manifestation with no clear genetic predisposition (idiopathic recurrent pericarditis), which often develops after a viral illness. Anakinra is highly effective in treating these patients and provides a rapid and sustained reduction in pain, particularly in patients refractory to conventional treatment with colchicine. Treating pericarditis with etanercept or infliximab has not been successful.

Myocarditis and Dilated Cardiomyopathy

30Clinical observations indicate a central role of IL-1 in the pathogenesis of cardiac inflammation. For example, myocardial involvement is part of the clinical spectrum of inflammatory or autoinflammatory diseases, such as AOSD or SOJIA, which are characteristically mediated by IL-1. IL-1 blockade is highly effective in these conditions, as exemplified by several published cases of myocarditis associated with SoJIA and AOSD and promptly controlled by anakinra. However, there is emerging evidence that anakinra can be effective in the treatment of fulminant myocarditis irrespective of the initiating trigger or underlying condition. In patients with myocarditis-associated acute heart failure, beneficial effects of anakinra on myocardial contractile function are particularly striking, and generally consistent with the observed benefit in patients with heart failure. It remains to be determined whether anakinra would increase myocardial function in non-acute myocarditis as it does in the acute condition. Blocking TNFα in myocarditis is contraindicated. There are case reports of anakinra treatment for myocarditis in patients non-responsive to anti-IL-6.

31A recent report described the efficacy of anakinra in a patient with dilated cardiomyopathy, a severe, irreversible heart disease characterized by left ventricular systolic dysfunction and dilation, which are not explained by abnormal loading or coronary artery disease. It is likely that several etiologic types of myocardial damage confluence in this common end-stage condition, which is histologically characterized by loss of contractile tissue, remodeling, and fibrosis. In the patient described in this study, histologic analyses of heart specimens had revealed subtle inflammation: treatment with IL-1 inhibition was thereby started, and led to a prompt clinical improvement in contractile function and arrhythmic burden. These results point at a possible role of low-grade chronic inflammation in the pathogenesis of dilated cardiomyopathy.

Diabetes and Metabolic Syndrome

32Interleukin-1-mediated inflammation plays a critical role in the progressive loss of β cells, which characterizes progression from insulin resistance to T2D. Specifically, IL-1β gene expression is dramatically elevated in β-cells of T2D patients compared to controls, whereas IL-1Ra levels are locally reduced and insufficient to protect β-cells from inflammation-mediated damage.

33Mechanistically, high glucose concentrations trigger β cells to produce IL-1β, which in turn contributes to β-cell loss by promoting deposition of amyloid. These pivotal observations delineated a new concept of T2D as a chronic inflammatory disease, in which IL-1-driven inflammation results in progressive loss of β cell function, and provided rationale for testing anakinra in T2D. In a randomized trial, treatment with anakinra for 13 weeks led to improved insulin production and glycemic control. Reduction in IL-1-mediated inflammation was confirmed by decreased levels of CRP and IL-6, and likely particularly relevant and sustained at the islet level, as treatment responders required 66% less insulin to maintain glycemic control in the 39 weeks following discontinuation. This pilot study led to subsequent, large trials of anti-IL-1β monoclonal antibodies gevokizumab, LY2189102, and – particularly – canakinumab in T2D, which all confirmed clinical benefits.

34Human fat tissue is an inflammatory environment in which infiltrating macrophages produce IL-1β. Anakinra treatment was thereby also evaluated in non-diabetic patients with metabolic syndrome, and was associated with a decrease in CRP and a corresponding increase in disposition index, thus reflecting improved β cell function.

35Given the association between cardiovascular disease and T2D, the potential of IL-1 blocking agents to improve cardiovascular health and glucose metabolism was assessed in the large CANTOS trial, which determined that treatment with the anti-IL-1β monoclonal antibody canakinumab reduces re-occurrence of ischemic events in patients with prior cardiovascular accidents. The CANTOS trial met its primary and secondary endpoints in both T2D subjects as well as in those without diabetes. Consistent with anakinra treatment in T2D, canakinumab reduced HbA1c during the first 6–9 months of treatment. However, after nearly 4 years of canakinumab treatment, prevention of progression to overt T2D in subjects with impaired glucose tolerance at enrollment was not observed and there was no sustained improvement in glycemic control. Thus, there is likely a role for IL-1α in T2D. Indeed, two studies in recent onset T1D tested anakinra versus canakinumab. Increased C-peptide was reported in subjects treated with anakinra but not canakinumab.

Rheumatoid Arthritis and Associated Comorbidities

36The efficacy of anakinra treatment in RA was evaluated in several controlled studies. Anakinra monotherapy or in association with methotrexate significantly reduced disease severity, joint space narrowing, radiographic joint damage, and bone erosions, while also improving quality of life. However, other biologics, including TNFα blockers, dominate the field of biologic treatments for RA. No direct comparison is available between the efficacy of IL-1 blockade and the overwhelming number of competing biologic agents; based upon indirect comparisons, anakinra seems moderately efficacious. Currently, anakinra is mostly administered to those RA patients in whom other biologics proved ineffective or are contraindicated, for example, due to previous malignancy or recurrent infections. In patients refractory to anti-TNFα therapy, anakinra was shown to be effective in controlling disease activity. Similar to anakinra, the anti-IL-1β monoclonal antibody canakinumab has reduced disease severity in RA patients, including those unresponsive to anti-TNFα therapies; however, unlike anakinra, long-term preservation of joint function with canakinumab remains unstudied.

37Compared to the general population, RA patients exhibit a higher incidence of T2D and cardiovascular events. In particular, infection and cardiovascular disease are the leading causes of death in RA patients, whereas T2D and metabolic syndrome are burdensome comorbidities. An ideal treatment should thereby not only reduce pain and prevent articular damage, but also aim at treating associated comorbidities with minimal adverse effects. Given the IL-1-mediated nature of these comorbidities, and the documented favorable effects of IL-1 blockade on cardiovascular and metabolic diseases (discussed above in the present review; ), benefits of anakinra in RA may extend beyond the mere efficacy on articular inflammation and are worth further exploration.

Gout and Other Forms of Crystal-Induced Arthritis

38Monosodium urate crystals activate the NLRP3 inflammasome and induce the release of active IL-1β, with a contribution of free fatty acids, which likely account for the diet-related flares of gout. Given the prominent neutrophil infiltration, extracellular processing by neutrophil proteases also likely accounts for activation of IL-1β precursor in gouty joints. Traditional options for managing acute flares include colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), and steroids. Treatment with anakinra is dramatically effective at dampening articular inflammation, while also resulting in prolonged periods without flares. Of note, the short half-life and excellent safety profile makes anakinra an ideal therapeutic option for the treatment of acute flares of gouty arthritis, and possibly of patients with underlying chronic kidney disease. Pyrophosphate crystal arthritis, a disease highly reminiscent of gout, is also characteristically responsive to anakinra, as is another common crystal-induced inflammatory condition, that is, acute calcific periarthritis of the shoulder. In these conditions, short-course anakinra treatment is associated with durable reduction of pain and function impairment, and with normalization of inflammatory indexes.

Osteoarthritis

39There is clinical and experimental evidence that IL-1 is involved in the pathogenesis of osteoarthritis. Thereby, previous studies evaluated the efficacy of direct instillation of anakinra into affected knee joints. Nevertheless, intra-articular injections of anakinra in patients with knee osteoarthritis yielded limited clinical benefit, which did not extend beyond one month from administration (possibly due to short-term persistence of anakinra in the joint space;, ). Anakinra has demonstrated some efficacy against joint pain and swelling in erosive osteoarthritis of the hand. IL-1 inhibition with antibodies to the IL-1 receptor has also been evaluated, again with only modest improvement. Recent data from the worldwide CANTOS trial supports a role for IL-1β in osteoarthritis. Although this was not the intent of the study, a highly significant reduction in osteoarthritis pain and improved joint function was reported by those treated with canakinumab compared to patients receiving placebo. Patients receiving 150 mg of canakinumab fives times each year reported a low incidence of osteoarthritis (1.67 per 100 person-years for placebo versus 1.12 for canakinumab, p < 0.001). Supporting evidence to a role for IL-1β in osteoarthritis from the CANTOS database is derived from (i) the large number of patients enrolled world-wide, (ii) the randomized, placebo controlled nature of the trial, and (iii) the specificity of IL-1β neutralization. The demographics of the CANTOS population include age, high BMI, and type 2 diabetes, each of which is characteristic of the osteoarthritis population. Not unexpectedly, there was also a significant reduction in gouty arthritis. Although canakinumab treatment was effective in reducing osteoarthritis, systemic treatment with anakinra or canakinumab is an unlikely therapy for the disease.

Role of IL-1 and IL-18 in Macrophage Activation Syndrome

40Macrophage activation syndrome (MAS), also known as hemophagocytic lympho-histiocytosis (HLH), is a rare, life-threatening condition characterized by a severe hyper-inflammatory state. It is clinically manifested with fever, elevated ferritin, liver enzymes, triglycerides, and pancytopenia due to phagocytosis of bone marrow hematopoietic precursors. Both genetic (familial HLH) and acquired forms of MAS have been described, the latter associated with infection with Epstein–Barr virus, cytomegalovirus, other herpes viruses, and intracellular bacteria, and also of various lymphomas, especially of T-cell lineage. The incidence of MAS is underestimated, as also suggested by new reports of MAS in patients with Ebola virus, parasitic, and influenza infections. In addition, patients with rheumatologic conditions, particularly SoJIA and AOSD but also systemic lupus erythematous, Kawasaki disease (KD), or systemic vasculitis can develop MAS.

41The pathogenesis of MAS is captivating increasing interest, and debate is ongoing as to whether MAS is prevalently mediated by IL-1 or IL-18. In the case of familial HLH, gene expression for IL-18 is upregulated in circulating mononuclear cells, and serum levels of IL-18 are unusually elevated. For comparison, levels of circulating IL-18 are below 1 ng/mL in inflammatory diseases such as severe sepsis, but can reach a 20–30 nm/mm range in MAS complicating systemic SoJIA. However, since an IL-18 neutralizing protein [IL-18 binding protein (IL-18BP)] is present in the circulation in health and promptly increases during inflammation, it is critical to determine the levels of free, biologically active IL-18. In patients with MAS, free IL-18 significantly correlated with clinical status and biologic markers of MAS, such as anemia, hypertriglyceridemia, and hyperferritinemia, but also with markers of Th1 lymphocyte or macrophage activation, such as IFNγ and soluble receptors for IL-2 and TNFα. A case of MAS due to a mutation in the NLRC4 inflammasome was successfully treated with IL-18BP, whereas anakinra therapy did not effectively reduce the severity of the disease.

42However, IL-1 is responsible for several signs and symptoms of MAS. For example, fever and the increase in ferritin levels are IL-1-mediated, since IL-18 does not cause fever, does not induce prostaglandins, and does not induce hepatic acute phase proteins. It should also be noted that IL-1 induces IL-18, and that this mechanism likely plays a critical role in MAS. For example, IL-1 induces the release of constitutively preformed IL-18 precursor from the endothelium. Elevated levels of IL-18 in MAS likely reflect release from IL-1-activated endothelium, rather than myeloid origin. IL-1-induced myocardial suppression is also mediated by IL-18. IL-1 mediates fever, hyperferritimia, coagulopathy, and production of IL-18; IL-18 likely mediates hypersplenism, hypertriglyceridemia, hypotension, and elevated IFNγ. With high levels of IL-18-dependent IFNγ, there is macrophage activation in the bone marrow and hemophagocytosis, which characterizes MAS.

Anakinra for MAS

43Anakinra has primarily been used in MAS due to SoIJA and occasionally to AOSD. Although most studies describe favorable results, reports of efficacy are mixed, and include some cases of SoJIA or AOSD who developed MAS while receiving therapy with IL-1 blockade. It is possible that development of MAS in these patients simply reflects extreme severity or inadequate control of underlying diseases. Indeed, increasing the dose of anakinra can result in clinical improvement.

44Hints of the efficacy of IL-1 blockade in MAS also come from clinical experience with septic shock. Many years ago, anakinra treatment was evaluated in three randomized, placebo-controlled trials of patients with sepsis or septic shock. In nearly 2000 patients enrolled in these trials, anakinra did not reduce overall all-cause mortality. However, recent re-analysis of data from these original studies revealed that a significant benefit of anakinra treatment could be identified in a subset of patients exhibiting a strikingly inflammatory phenotype, which was highly reminiscent of MAS and clinically characterized by cytopenia and elevated ferritin and liver enzymes levels.

Behcet’s Disease

45Behçet’s disease is a rare vasculitis of small- and medium-sized vessels characterized by ocular and cutaneous inflammation, oral and genital ulcers, gastrointestinal or brain vasculitis, and hypercoagulable state. Ocular involvement may cause organ-threatening uveitis and retinal vasculitis. Severe, steroid-resistant disease responds to IL-1 blockers, which can afford dramatic and sustained reversal of intraocular inflammation.

46In an open-label pilot study of anti-IL-1β antibodies (gevokizumab) in the treatment of acute eye inflammation, a single dose prompted complete resolution of pan-uveitis and restored normal vision within 4–21 days.

Systemic Vasculitides: Kawasaki Disease, Takayasu Arteritis, Giant Cell Arteritis

47Kawasaki disease is one of the most common systemic vasculitides and a leading cause of acquired heart disease in children. It typically affects coronary arteries, and residual vascular damage can cause complications later in life, including myocardial infarctions. Classic treatment options include intravenous immunoglobulin (IVIG) and aspirin. Of note, the beneficial anti-inflammatory and therapeutic effects of IVIG in several immune-mediated disorders include a reduction in IL-1 production with an increase in IL-1Ra. Consistently, reports on the efficacy of anakinra treatment indicate that IL-1 plays a pivotal role in the development of vascular damage in KD. A prospective trial on anakinra in KD is underway (NCT02179853).

48Coronary and peripheral artery inflammation also characterizes large vessel vasculitides Takayasu and giant cell arteritis. Therapies for steroid- and DMARD-refractory large vessel vasculitides are limited. Analysis of temporal artery specimens from GCA patients revealed that IL-1 is highly expressed in inflamed vessels: accordingly, anakinra treatment dampened systemic and arterial inflammation in two cases refractory to conventional treatment.

Histiocytic Disorders

49Erdheim–Chester disease (ECD) is a rare form of non-Langerhans histiocytosis, characterized by infiltration of foamy macrophages into multiple tissues. The disease is typically sustained by activating mutations along the mitogen-activated protein kinase (MAPK) or related pathways in macrophages, which lead to cell activation and consequent production of high levels of pro-inflammatory cytokines and fibrosis of affected tissues. Clinical manifestations include bone pain, neurological symptoms, retroperitoneal fibrosis, and congestive heart failure. Anakinra is effective in ameliorating skeletal, cardiac, retroperitoneal, and systemic manifestations, thus substantiating the central role of macrophages in diseases responsive to IL-1 blockade. Interestingly, a traditional treatment option for ECD, that is, alpha interferon (IFNα), may exert beneficial effects via induction of IL-1Ra and inhibition of inflammasome activation. Modulation of the IL-1 pathway may indeed explain the efficacy of IFNα in the management of ECD, as well as in a spectrum of clinical conditions similarly characterized by the BRAFV600E mutation and activation of the IL-1 pathway, including hairy cell leukemia and melanoma.

Hearing Loss in Autoinflammatory Syndromes

50Sensorineural deafness is a prominent characteristic of CAPS, a spectrum of conditions caused by activating mutations in NLRP3 leading to deregulated release of active IL-1β, which are effectively treated with IL-1 blockade. The first reports of reversal in sensorineural deafness with anakinra came from patients with MWS, a CAPS subtype; several other reports followed. This reversal in sensorineural deafness with anakinra treatment delineated the unexpected concept that hearing loss in autoinflammatory diseases is due to a reversible chronic inflammatory response, rather than permanent loss of neuronal function. Nevertheless, early treatment with anakinra is more likely to be beneficial. Patients with NOMID, a more severe disease also part of the CAPS spectrum, also benefit from anakinra treatment for hearing loss. In pediatric patients with CAPS, early identification in childhood and early anakinra treatment prevents or rescues sensorineural deafness and hearing loss, and results in normal intellectual development into adulthood (; #7023; ).

Anakinra in Autoimmune Hearing Loss

51Sensorineural deafness also occurs in vasculitis and autoimmune inner ear disease, and is clinically manifested as rapidly progressive, often irreversible hearing loss. Treatment relies on high-dose glucocorticoids, but many patients are refractory or become unresponsive over time. In these refractory cases, elevated IL-1β was demonstrated in the circulation and in monocyte cultures. In an open-label, single-arm, phase I/II clinical trial of anakinra in corticosteroid-resistant autoimmune inner ear disease, 10 patients received treatment for 12 weeks. Of these, seven obtained audiometric improvement, paralleled by reduced IL-1β plasma levels.

Dry Eye Disease

52Dry eye syndrome, or keratoconjunctivitis sicca, is a common, multifactorial disorder of the eye characterized by deficient tear production, excessive tear evaporation, or both. Meibomian gland dysfunction is thought to be the leading cause of this condition, which results in discomfort, visual disturbance, and ocular surface damage. Topical administration of low-dose (2.5%) anakinra proved effective in a randomized clinical trial of 75 dry eye disease patients, which achieved a significant reduction in mean severity score and symptoms. It is tempting to envisage similarly favorable results in patients with Sjögren and sicca syndrome.

Pulmonary Silicosis

53Pulmonary silicosis is an occupational disease caused by inhalation of silica crystals. These are not effectively cleared by alveolar macrophages and induce a chronic inflammatory response eventually leading to pulmonary fibrosis and progressive respiratory insufficiency. Since silica crystals activate the inflammasome and trigger release of active IL-1β, a study evaluated anakinra treatment and documented progressive improvement in respiratory symptoms and pulmonary inflammation in a patient with pulmonary silicosis and severe respiratory failure.

Organ Transplant

54Previous studies identified associations between levels of IL-1β and IL-1Ra in serum and urine and negative graft outcome; studies in experimental animals and observations in humans also substantiated a possible protective effect of blocking IL-1 after solid organ transplantation (reviewed in ). New evidence suggests that in patients undergoing solid organ transplantation, IL-1 inhibition in addition to standard immunosuppressive regimens may dampen inflammation and protect against negative graft outcome. Three patients undergoing renal transplantation were receiving treatment with anakinra in the peri-operative and post-operative period for underlying IL-1-driven autoinflammatory diseases (AOSD, CAPS, and FMF, respectively). Kidney function increased rapidly in all patients; anakinra was well tolerated and safe with the exception of minor infections. The beneficial effects of treatment are likely due to dampening of ischemia-reperfusion injury, which accompanies renal transplantation and leads to release of IL-1 and to impaired graft function.

Anakinra for Central Nervous System Diseases

55Neurologic complications observed in CAPS patients reveal the effects of IL-1-mediated inflammation in the brain. Common clinical manifestations include headache or migraine, sensory-neural hearing loss, papilledema due to elevated intracranial pressure, and mental impairment. IL-1 blockade with anakinra or canakinumab reverses neurologic inflammation and related symptoms, including mental and hearing impairment.

Anakinra Enters the Brain

56The first evidence that anakinra administered peripherally crossed the blood–brain barrier and reduced severity of a disease primarily localized to the central nervous system came from NOMID. Specifically, 12 children with NOMID were treated with 1–2 mg/kg of subcutaneous anakinra daily. The median cerebrospinal fluid (CSF) level of IL-1Ra was 211 pg/mL before treatment, but rose to 1136 pg/mL after 3 months of treatment. These effects were associated with a remarkable decrease in the severity of various NOMID manifestations, including elevated intracranial pressure, leptomeningitis, and neurosensorial hearing loss, as well as reduced CSF levels of IL-6.

57Intravenous anakinra was also administered to patients with subarachnoid hemorrhage due to aneurysmal rupture, again in a placebo-controlled setting. Within 72 h of the acute event, patients received a bolus infusion of 500 mg of anakinra followed by a steady infusion of 10 mg/kg/h for 24 h. At 24 h, CSF levels of IL-6 were reduced in the anakinra compared to the placebo group.

58A related study investigated the dose regimen necessary to obtain a CSF concentration of anakinra 100 ng/mL. This concentration (100 ng/mL) was deemed neuro-protective based on studies of rats subjected to brain ischemia; as for human reference, this target concentration of 100 ng/mL is 100-fold greater than that in the CSF of children receiving subcutaneous anakinra 100 mg daily for 3 months. In this study, patients with subarachnoid bleed received incremental doses of intravenous anakinra: specifically, the patients received a bolus dose of anakinra (100–500 mg) followed by a 4-h infusion of anakinra from 1 to 10 mg/kg/h. Levels of anakinra were monitored in plasma and CSF (collected through a cerebral ventricular drain). A target CSF level of 100 ng/mL was achieved with the highest regimen (a bolus of 500 mg followed by 4 h of anakinra at 10 mg/kg/h;; ). The authors concluded that anakinra passively enters the brain in patients with a subarachnoid hemorrhage: therefore, a high-dose regimen of anakinra may reduce inflammation, infiltration of neutrophils, and edema at the site of the lesion. In a subsequent randomized study, patients with subarachnoid hemorrhage received anakinra 100 mg twice daily subcutaneously within 3 days of stroke and for the following 21 days. Again, anakinra treatment significantly reduced levels of inflammatory markers IL-6, CRP, and fibrinogen. Although these studies were not powered to determine clinical effects, scores of the Glasgow Outcome Scale at 6 months were better, albeit not significantly, among patients receiving anakinra. Whether dampening of IL-1-mediated inflammation will result in improved neurological outcomes remains to be determined in adequately powered, randomized, placebo-controlled studies.

59In a different study, intravenous anakinra was administered to patients admitted to the hospital within 6 h of an acute thrombotic stroke. This trial included 34 patients and was randomized and placebo controlled; anakinra was administered at a high dose of 2 mg/kg/h for 72 h, analogous to inception trials of anakinra in septic shock. Compared to placebo-treated controls, patients treated with anakinra had lower IL-6, CRP, and neutrophil levels. Although the study was not powered for detecting significant improvements in neurological outcomes, the subgroup of patients with cortical infarcts receiving anakinra performed better compared to the placebo group.

60Additional evidence that anakinra crosses the blood brain barrier and exerts anti-inflammatory effects in the brain comes from studies of traumatic brain injury, a major cause of death and disability worldwide, particularly in young persons. In a randomized, open-label trial, 20 patients who had suffered diffuse traumatic brain injury within the previous 24 h received either anakinra 100 mg daily for 5 days or placebo. A central microdialysis catheter was placed in each patient as part of standard of care. Prior to administration of anakinra, the mean level of IL-1Ra in the CSF was 78 pg/mL but rose to 138 pg/mL 12 h after the first dose. In general, inflammatory cytokines in the CSF were lower in patients treated with anakinra; of these, macrophage-derived chemoattractant-1 (MDC-1) was remarkably lower compared to patients treated with the placebo (1.04 pg/mL in the anakinra group compared to 45.4 pg/mL in the placebo group; ). The study was not powered to evaluate clinical improvement, although the marked decrease in CSF levels of cytokines and MDC-1 argue in favor of beneficial anti-inflammatory effects.

Epilepsy

61Although IL-1α is found in brain astrocytes and microglia, available data point at IL-1β as the main contributor to epileptic seizures. Several studies have focused on febrile seizures since these are among the most common type of seizure activity. Using an animal model for febrile seizures, an agonist role for IL-1β and an antagonist role for endogenous IL-1Ra in the hippocampus have been reported. Other studies examined circulating cytokines in patients with recurrent seizures, and revealed elevated levels of IL-6 and IL-1Ra in the post-acute period. In one study, high levels of IL-1β were also observed during acute episodes of recurrent temporal lobe epilepsy. Some studies have reported polymorphisms in IL-1α, IL-1β, and IL-1Ra in subjects who develop epilepsy as adults. In experimental animals, suppression of peripheral IL-1-mediated inflammation reduces the severity of status epilepticus.

62Anakinra has been administered to a young patient with a severe seizure disorder termed febrile infection-related epilepsy syndrome (FIRES; ). This syndrome, which often follows an infectious encephalopathy, has a high mortality rate and few treatment options. This patient had recurrent seizures each day, which progressively decreased in frequency and eventually ceased while being treated with daily subcutaneous anakinra. This was mirrored by a decrease in CSF pro-inflammatory cytokines. When anakinra was stopped, seizures resumed only to decrease again upon restarting. A subsequent study confirmed the favorable outcome with anakinra described in this report. Anakinra was administered to five children with FIRES and refractory status epilepticus beginning shortly after a febrile illness. All had received anti-epileptic drugs (AEDs, ranging from two to six different medications), had required anesthetics for seizure control, and had received treatment with corticosteroids and IVIG; three underwent plasmapheresis. Anakinra was initiated on day 12–32 of illness at a dose ranging from 3 to 7 mg/kg/day, and led to rapid and remarkable clinical improvement in all but one patient. Specifically, seizure count in the week prior to anakinra initiation ranged from 8 to 170, but dropped to 0–12 after 1 week of anakinra treatment and to 0–7 after 4 weeks of treatment. Two patients had increased seizure burden upon anakinra weaning or discontinuation, again substantiating the role of IL-1 in seizure disorder. In another study, an adolescent female with signs of persistent systemic inflammation and epilepsy unresponsive to multiple AEDs also promptly responded to anakinra.

Safety of Il-1 Blockade With Anakinra

63Impaired host defense against pathogens is a concern for cytokine-blocking agents. In patients treated with biologics, particularly TNFα blocking therapies, there is an increased risk of several opportunistic infections, similar to those observed in immunosuppressed persons. Host defense against opportunistic organisms as well as common bacterial infections have since become a major concern for all anti-cytokine agents because of the indolent and dangerous nature of these infections. For example, reactivation of latent M. tuberculosis in patients receiving anti-TNFα therapies can be 25 times higher than in untreated persons and is often in the disseminated form, similar to that observed in HIV-1 infected patients. M. tuberculosis also occurs in patients treated with TNFα blockers without evidence of prior exposure to the organism. Despite screening for previous exposure to M. tuberculosis before beginning any anti-cytokine treatment, reactivation continues to occur and can be as high as 9.3%.

64As with all biologic agents, an increase in infection frequency has been reported for anakinra. Nevertheless, in comparison to other biologic agents, anakinra has an unparalleled safety benefit deriving from short half-life and effect duration, and has demonstrated a remarkable record of safety. Since introduction in 2002, it is estimated that over 150,000 patients have received anakinra, some treated daily for over 10 years. Opportunistic infections in patients treated with anakinra are rare, including in populations at high risk for reactivation of M. tuberculosis infections. There is a single case report of a 77-year-old man with severe RA and a history of pulmonary tuberculosis who developed a reactivation 23 months after starting anakinra.

65In addition, a large number of animal studies including primates subjected to live bacteria inoculum demonstrated greater survival in infected animals treated with anakinra compared to vehicle. In humans, anakinra has been administered to patients with active infections, and in over 2000 patients in trials of sepsis and septic shock without any increase in mortality despite exceedingly high dosing (30-fold higher than the current approved dose of 100 mg/day; ). Other safety examples include hidradenitis suppurativa, in which anakinra treatment resolves inflammation of Staphylococcus aureus-infected apocrine glands, and chronic granulomatous disease, an inherited condition with recurrent bouts of infections with Gram-positive and Gram-negative bacteria as well as fungi: in both conditions, treatment with anakinra reduces the severity of inflammation without increasing the infection burden.

66During controlled trials of anakinra, there were more viral-type upper airway infections compared to placebo-treated patients, as for most other biologics. There are two spurious reports of anakinra-related hepatotoxicity in patients with AOSD; however, withdrawal of anakinra restored normal liver function. Of note, there are several reports of the safety of increasing the dose of anakinra to 200 mg/day or above.

67Subcutaneous administrations of anakinra often cause injection site reactions. Albeit uncomfortable due to the need for daily injections, these usually resolve within 2–3 weeks of treatment initiation. A fraction of patients receiving treatment with anakinra can develop antibodies against the drug. As with other biologic agents, the potential for adverse effects including hypersensitivity reactions or aplasia should be carefully monitored. Conversely, these antibodies are usually non-neutralizing and do not decrease the biologic effectiveness of anakinra, nor they appear to be linked to the development of injection site reaction.

68Interleukin-1 injected into humans at doses as low as 3 ng/kg induce neutrophil mobilization from the bone marrow and neutrophilia. Hence, most patients with IL-1-mediated conditions exhibit neutrophilia as a hematological manifestation of their disease. A reduction in circulating neutrophils upon anakinra administration can be observed and often heralds a clinical response; sustained neutropenia is not typically observed, but neutrophil levels occasionally fall below the normal range, only to rise rapidly upon cessation of treatment.

Author Contributions

69GC and CD wrote the manuscript.

Conflict of Interest Statement

70The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 285

1.
Abbate A. Kontos M. C. Grizzard J. D. Biondi-Zoccai G. G. Van Tassell B. W. Robati R. (2010 ). Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am. J. Cardiol. 105 1371.e1–1377.e1.
Not in our library10.1016/j.amjcard.2009.12.059
2.
Abbate A. Van Tassell B. W. Biondi-Zoccai G. Kontos M. C. Grizzard J. D. Spillman D. W. (2013 ). Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am. J. Cardiol. 111 1394–1400.
Not in our library10.1016/j.amjcard.2013.01.287
3.
Aganna E. Martinon F. Hawkins P. N. Ross J. B. Swan D. C. Booth D. R. (2002 ). Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum. 46 2445–2452.
Not in our library10.1002/art.10509
4.
Agostini L. Martinon F. Burns K. McDermott M. F. Hawkins P. N. Tschopp J. (2004 ). NALP3 forms an IL-1beta processing inflammasome with increased activity in muckle-wells auto-inflammatory disorder. Immunity 20 319–325.
Not in our library10.1016/s1074-7613(04)00046-9
5.
Ahmadi N. Brewer C. C. Zalewski C. King K. A. Butman J. A. Plass N. (2011 ). Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations. Otolaryngol. Head Neck Surg. 145 295–302.
Not in our library10.1177/0194599811402296
6.
Ait-Abdesselam T. Lequerre T. Legallicier B. Francois A. Le Loet X. Vittecoq O. (2011 ). Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome. Joint Bone Spine 77 616–617.
Not in our library10.1016/j.jbspin.2010.04.018
7.
Aksentijevich I. Masters S. L. Ferguson P. J. Dancey P. Frenkel J. van Royen-Kerkhoff A. (2009 ). An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360 2426–2437.
Not in our library10.1056/nejmoa0807865
8.
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study · 2011
No notice
9.
Ambrose N. L. O’Connell P. G. (2007 ). Anti-TNF alpha therapy does not always protect rheumatoid arthritis patients against developing pericarditis. Clin. Exp. Rheumatol. 25:660.
Not in our library
10.
Amparo F. Dastjerdi M. H. Okanobo A. Ferrari G. Smaga L. Hamrah P. (2013 ). Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol. 131 715–723.
Not in our library10.1001/jamaophthalmol.2013.195
11.
Announ N. Palmer G. Guerne P. A. Gabay C. (2009 ). Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 76 424–426.
Not in our library10.1016/j.jbspin.2009.01.001
12.
Aouba A. Georgin-Lavialle S. Pagnoux C. Martin Silva N. Renand A. Galateau-Salle F. (2010 ). Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 116 4070–4076.
Not in our library10.1182/blood-2010-04-279240
13.
Arend W. P. Joslin F. G. Massoni R. J. (1985 ). Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J. Immunol. 134 3868–3875.
Not in our library
14.
Aronson I. K. Worobec S. M. (2010 ). Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview. Dermatol. Ther. 23 389–402.
Not in our library10.1111/j.1529-8019.2010.01339.x
15.
Arostegui J. I. Arnal C. Merino R. Modesto C. Antonia Carballo M. Moreno P. (2007 ). NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 56 3805–3813.
Not in our library10.1002/art.22966
16.
Aukrust P. Froland S. S. Liabakk N. B. Muller F. Nordoy I. Haug C. (1994 ). Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84 2136–2143.
Not in our library
17.
Auron P. E. Webb A. C. Rosenwasser L. J. Mucci S. F. Rich A. Wolff S. M. (1984 ). Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl. Acad. Sci. U.S.A. 81 7907–7911.
Not in our library10.1073/pnas.81.24.7907
18.
Bacconnier L. Jorgensen C. Fabre S. (2009 ). Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann. Rheum. Dis. 68 1078–1079.
Not in our library10.1136/ard.2008.094284
19.
Balavoine J. F. de Rochemonteix B. Williamson K. Seckinger P. Cruchaud A. Dayer J.-M. (1984 ). Identification of interleukin 1-like activity and inhibitor(s) in urine from a patient with acute monoblastic leukemia. Lymphokine Res. 3:23.
Not in our library
20.
Balavoine J. F. de Rochemonteix B. Williamson K. Seckinger P. Cruchaud A. Dayer J. M. (1986 ). Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J. Clin. Invest. 78 1120–1124.
Not in our library10.1172/jci112669
21.
Ballak D. B. Li S. Cavalli G. Stahl J. L. Tengesdal I. W. van Diepen J. A. (2018 ). Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. J. Biol. Chem. 293 14224–14236.
Not in our library10.1074/jbc.ra118.003698
22.
Behrens E. M. Kreiger P. A. Cherian S. Cron R. Q. (2006 ). Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J. Rheumatol. 33 2081–2084.
Not in our library
23.
Belani H. Gensler L. Bajpai U. Meinhardt E. Graf J. Pincus L. (2013 ). Neutrophilic urticaria with systemic inflammation: a case series. JAMA Dermatol. 149 453–458.
Not in our library10.1001/jamadermatol.2013.2705
24.
Berti A. Campochiaro C. Cavalli G. Pepe G. Praderio L. Sabbadini M. G. (2015 ). Giant cell arteritis restricted to the limb arteries: an overlooked clinical entity. Autoimmun. Rev. 14 352–357.
Not in our library10.1016/j.autrev.2014.12.005
25.
Berti A. Cavalli G. Guglielmi B. Biavasco R. Campochiaro C. Tomelleri A. (2017 ). Tocilizumab in patients with multisystem erdheim-chester disease. Oncoimmunology 6:e1318237.
Not in our library10.1080/2162402x.2017.1318237
26.
Blonz G. Lacroix S. Benbrik N. Warin-Fresse K. Masseau A. Trewick D. (2018 ). Severe late-onset kawasaki disease successfully treated with anakinra. J. Clin. Rheumatol. [Epub ahead of print].
Not in our library10.1097/rhu.0000000000000814
27.
Bodar E. J. Kuijk L. M. Drenth J. P. van der Meer J. W. Simon A. Frenkel J. (2011 ). On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann. Rheum. Dis. 70 2155–2158.
Not in our library10.1136/ard.2011.149922
28.
β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion · 2018
Not checked
29.
Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis · 2011
Not checked
30.
Boyer E. M. Turman M. O’Neil K. M. (2011 ). Partial response to anakinra in life-threatening Henoch-Schonlein purpura: case report. Pediatr. Rheumatol. J. 9:21.
Not in our library10.1186/1546-0096-9-21
31.
Braun-Falco M. Kovnerystyy O. Lohse P. Ruzicka T. (2011 ). Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. J. Am. Acad. Dermatol. 66 409–415.
Not in our library10.1016/j.jaad.2010.12.025
32.
Brenner M. Ruzicka T. Plewig G. Thomas P. Herzer P. (2009 ). Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br. J. Dermatol. 161 1199–1201.
Not in our library10.1111/j.1365-2133.2009.09404.x
33.
Bresnihan B. Alvaro-Gracia J. M. Cobby M. Doherty M. Domljan Z. Emery P. (1998 ). Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41 2196–2204.
Not in our library10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2
34.
Bresnihan B. Newmark R. Robbins S. Genant H. K. (2004 ). Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J. Rheumatol. 31 1103–1111.
Not in our library
35.
Brucato A. Imazio M. Gattorno M. Lazaros G. Maestroni S. Carraro M. (2016 ). Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical Trial. JAMA 316 1906–1912.
Not in our library10.1001/jama.2016.15826
36.
Buckley L. F. Abbate A. (2018 ). Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur. Heart J. 39 2063–2069.
Not in our library10.1093/eurheartj/ehy128
37.
Cain B. S. Meldrum D. R. Dinarello C. A. Meng X. Joo K. S. Banerjee A. (1999 ). Tumor necrosis factor-a and interleukin-1b synergistically depress human myocardial function. Crit. Care Med. 27 1309–1318.
Not in our library10.1097/00003246-199907000-00018
38.
Campochiaro C. Tomelleri A. Cavalli G. Berti A. Dagna L. (2015 ). Erdheim-chester disease. Eur. J. Intern. Med. 26 223–229.
Not in our library10.1016/j.ejim.2015.03.004
39.
Cangi M. G. Biavasco R. Cavalli G. Grassini G. Dal-Cin E. Campochiaro C. (2015 ). BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann. Rheum. Dis. 74 1596–1602.
Not in our library10.1136/annrheumdis-2013-204924
40.
Canna S. W. Girard C. Malle L. de Jesus A. Romberg N. Kelsen J. (2017 ). Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J. Allergy Clin. Immunol. 139 1698–1701.
Not in our library10.1016/j.jaci.2016.10.022
41.
Cannon J. G. Dinarello C. A. (1985 ). Increased plasma interleukin-1 activity in women after ovulation. Science 227 1247–1249.
Not in our library10.1126/science.3871966
42.
Cantarini L. Lopalco G. Caso F. Costa L. Iannone F. Lapadula G. (2015a ). Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet’s disease. Autoimmun. Rev. 14 1–9.
Not in our library10.1016/j.autrev.2014.08.008
43.
Cantarini L. Vitale A. Scalini P. Dinarello C. A. Rigante D. Franceschini R. (2015b ). Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin. Rheumatol. 34 1293–1301.
Not in our library10.1007/s10067-013-2443-8
44.
Cantarini L. Lucherini O. M. Cimaz R. Galeazzi M. (2010 ). Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin. Exp. Rheumatol. 28:802.
Not in our library
45.
Cantarini L. Lucherini O. M. Cimaz R. Rigante D. Baldari C. T. Laghi Pasini F. (2012a ). Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series. Rheumatol. Int. 32 4015–4018.
Not in our library10.1007/s00296-010-1512-4
46.
Cantarini L. Lucherini O. M. Muscari I. Frediani B. Galeazzi M. Brizi M. G. (2012b ). Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun. Rev. 12 38–43.
Not in our library10.1016/j.autrev.2012.07.020
47.
Cavalli G. Berti A. Campochiaro C. Dagna L. (2013a ). Diagnosing erdheim-chester disease. Ann. Rheum. Dis. 72:e19.
Not in our library10.1136/annrheumdis-2013-203685
48.
Cavalli G. Guglielmi B. Berti A. Campochiaro C. Sabbadini M. G. Dagna L. (2013b ). The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann. Rheum. Dis. 72 1691–1695.
Not in our library10.1136/annrheumdis-2012-202542
49.
Cavalli G. Biavasco R. Borgiani B. Dagna L. (2014 ). Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease. Front. Immunol. 5:281.
Not in our library10.3389/fimmu.2014.00281
50.
Cavalli G. De Luca G. Dagna L. (2017a ). Advances in potential targeted therapies for erdheim-chester disease. Expert Opin. Orphan Drugs 5 253–260. 28598870
Not in our library10.1080/21678707.2017.1285226
51.
Cavalli G. Foppoli M. Cabrini L. Dinarello C. A. Tresoldi M. Dagna L. (2017b ). Interleukin-1 Receptor blockade rescues myocarditis-associated end-stage heart failure. Front. Immunol. 8:131.
Not in our library10.3389/fimmu.2017.00131
52.
Cavalli G. Justice J. N. Boyle K. E. D’Alessandro A. Eisenmesser E. Z. Herrera J. J. (2017c ). Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proc. Natl. Acad. Sci. U.S.A. 114 2313–2318.
Not in our library10.1073/pnas.1619011114
53.
Cavalli G. Koenders M. Kalabokis V. Kim J. Choon Tan A. Garlanda C. (2017d ). Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology 56 2220–2229.
Not in our library10.1093/rheumatology/kex348
54.
Cavalli G. Dinarello C. A. (2015 ). Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology 54 2134–2144.
Not in our library10.1093/rheumatology/kev269
55.
Cavalli G. Dinarello C. A. (2018 ). Suppression of inflammation and acquired immunity by IL-37. Immunol. Rev. 281 179–190.
Not in our library10.1111/imr.12605
56.
Cavalli G. Fallanca F. Dinarello C. A. Dagna L. (2015a ). Treating pulmonary silicosis by blocking interleukin 1. Am. J. Respir. Crit. Care Med. 191 596–598.
Not in our library10.1164/rccm.201412-2150le
57.
Cavalli G. Franchini S. Aiello P. Guglielmi B. Berti A. Campochiaro C. (2015b ). Efficacy and safety of biological agents in adult-onset Still’s disease. Scand. J. Rheumatol. 44 309–314.
Not in our library10.3109/03009742.2014.992949
58.
Cavalli G. Hayashi M. Jin Y. Yorgov D. Santorico S. A. Holcomb C. (2016a ). MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proc. Natl. Acad. Sci. U.S.A. 113 1363–1368.
Not in our library10.1073/pnas.1523482113
59.
Cavalli G. Koenders M. Kalabokis V. Kim J. Tan A. C. Garlanda C. (2016b ). Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology 55 2220–2229.
Not in our library10.1093/rheumatology/kew325
60.
Cavalli G. Pappalardo F. Mangieri A. Dinarello C. A. Dagna L. Tresoldi M. (2016c ). Treating life-threatening myocarditis by blocking interleukin-1. Crit. Care Med. 44 e751–e754.
Not in our library10.1097/ccm.0000000000001654
61.
Cavalli G. Tomelleri A. Di Napoli D. Baldissera E. Dagna L. (2018 ). Prevalence of Takayasu arteritis in young women with acute ischemic heart disease. Int. J. Cardiol. 252 21–23.
Not in our library10.1016/j.ijcard.2017.10.067
62.
Cavelti-Weder C. Babians-Brunner A. Keller C. Stahel M. A. Kurz-Levin M. Zayed H. (2012 ). Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35 1654–1662.
Not in our library10.2337/dc11-2219
63.
Chae J. J. Wood G. Masters S. L. Richard K. Park G. Smith B. J. (2006 ). The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc. Natl. Acad. Sci. U.S.A. 103 9982–9987.
Not in our library10.1073/pnas.0602081103
64.
Chevalier X. Giraudeau B. Conrozier T. Marliere J. Kiefer P. Goupille P. (2005 ). Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J. Rheumatol. 32 1317–1323.
Not in our library
65.
Chevalier X. Goupille P. Beaulieu A. D. Burch F. X. Bensen W. G. Conrozier T. (2009 ). Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 61 344–352.
Not in our library10.1002/art.24096
66.
Chiapparini L. Cavalli G. Langella T. Venerando A. De Luca G. Raspante S. (2018 ). Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease. J. Neurol. 265 273–284.
Not in our library10.1007/s00415-017-8692-8
67.
Chiu H. Y. Hsueh P. R. Tsai T. F. (2011 ). Clinical experience of QuantiFERON((R)) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br. J. Dermatol. 164 553–559.
Not in our library10.1111/j.1365-2133.2010.10137.x
68.
Choi A. D. Moles V. Fuisz A. Weissman G. (2014 ). Cardiac magnetic resonance in myocarditis from adult onset Still’s disease successfully treated with anakinra. Int. J. Cardiol. 172 e225–e227.
Not in our library10.1016/j.ijcard.2013.12.151
69.
Chou I. C. Lin W. D. Wang C. H. Tsai C. H. Li T. C. Tsai F. J. (2010 ). Interleukin (IL)-1beta, IL-1 receptor antagonist, IL-6, IL-8, IL-10, and tumor necrosis factor alpha gene polymorphisms in patients with febrile seizures. J. Clin. Lab. Anal. 24 154–159.
Not in our library10.1002/jcla.20374
70.
Clark S. R. McMahon C. J. Gueorguieva I. Rowland M. Scarth S. Georgiou R. (2008 ). Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J. Cereb. Blood Flow Metab. 28 387–394.
Not in our library10.1038/sj.jcbfm.9600537
71.
Cohen S. Hurd E. Cush J. Schiff M. Weinblatt M. E. Moreland L. W. (2002 ). Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46 614–624.
Not in our library10.1002/art.10141
72.
Cohen S. Tacke C. E. Straver B. Meijer N. Kuipers I. M. Kuijpers T. W. (2012 ). A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Ann. Rheum. Dis. 71 2059–2061.
Not in our library10.1136/annrheumdis-2012-201658
73.
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee · 2011
No notice
74.
Colafrancesco S. Priori R. Valesini G. Argolini L. Baldissera E. Bartoloni E. (2017 ). Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still’s disease: a multicentre retrospective observational study. Front. Pharmacol. 8:369
Not in our library10.3389/fphar.2017.00369
75.
Colina M. Pizzirani C. Khodeir M. Falzoni S. Bruschi M. Trotta F. (2010 ). Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology 49 1416–1418.
Not in our library10.1093/rheumatology/keq074
76.
de Koning H. D. Schalkwijk J. van der Ven-Jongekrijg J. Stoffels M. van der Meer J. W. Simon A. (2013 ). Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann. Rheum. Dis. 72 1634–1638.
Not in our library10.1136/annrheumdis-2012-202192
77.
de Koning H. D. van Gijn M. E. Stoffels M. Jongekrijg J. Zeeuwen P. L. Elferink M. G. (2015 ). Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J. Allergy Clin. Immunol. 135 561–564.
Not in our library10.1016/j.jaci.2014.07.050
78.
De Luca G. Campochiaro C. Dinarello C. A. Dagna L. Cavalli G. (2018a ). Treatment of dilated cardiomyopathy with interleukin-1 inhibition. Ann Intern. Med. [Epub ahead of print].
Not in our library10.7326/l18-0315
79.
De Luca G. Cavalli G. Campochiaro C. Tresoldi M. Dagna L. (2018b ). Myocarditis: an interleukin-1-mediated disease? Front. Immunol. 9:1335.
Not in our library10.3389/fimmu.2018.01335
80.
De Luca G. Cavalli G. Baldissera E. Dagna L. (2017 ). Assessing the role of pentraxin-3 in Takayasu’s arteritis. comment on: plasma pentraxin-3 levels in patients with takayasu’s arteritis during routine follow-up. Alibaz-Oner F. et al. Clin. Exp. Rheumatol. 103:221.
Not in our library
81.
Delluc A. Limal N. Puechal X. Frances C. Piette J. C. Cacoub P. (2008 ). Efficacy of anakinra, an IL1 receptor antagonist, in refractory sweet syndrome. Ann. Rheum. Dis. 67 278–279.
Not in our library10.1136/ard.2006.068254
82.
DeSena A. D. Do T. Schulert G. S. (2018 ). Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade. J Neuroinflammation 15:38.
Not in our library10.1186/s12974-018-1063-2
83.
Devasahayam J. Pillai U. Lacasse A. (2012 ). A rare case of pericarditis, complication of infliximab treatment for Crohn’s disease. J. Crohns Colitis 6 730–731.
Not in our library10.1016/j.crohns.2012.02.016
84.
Diamond E. L. Abdel-Wahab O. Durham B. H. Dogan A. Ozkaya N. Brody L. (2016 ). Anakinra as efficacious therapy for two cases of intracranial Erdheim-Chester disease. Blood 128 1896–1898.
Not in our library10.1182/blood-2016-06-725143
85.
Diamond E. L. Dagna L. Hyman D. M. Cavalli G. Janku F. Estrada-Veras J. (2014 ). Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124 483–492.
Not in our library10.1182/blood-2014-03-561381
86.
Dierselhuis M. P. Frenkel J. Wulffraat N. M. Boelens J. J. (2005 ). Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 44 406–408.
Not in our library10.1093/rheumatology/keh479
87.
Dinarello C. A. (1996 ). Biological basis for interleukin-1 in disease. Blood 87 2095–2147.
Not in our library
88.
Dinarello C. A. (2015 ). The history of fever, leukocytic pyrogen and interleukin-1. Temperature 2 8–16.
Not in our library10.1080/23328940.2015.1017086
89.
Dinarello C. A. Goldin N. P. Wolff S. M. (1974 ). Demonstration and characterization of two distinct human leukocytic pyrogens. J. Exp. Med. 139 1369–1381.
Not in our library10.1084/jem.139.6.1369
90.
Dinarello C. A. Ikejima T. Warner S. J. Orencole S. F. Lonnemann G. Cannon J. G. (1987 ). Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J. Immunol. 139 1902–1910.
Not in our library
91.
Dinarello C. A. Renfer L. Wolff S. M. (1977 ). Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc. Natl. Acad. Sci. U.S.A. 74 4624–4627.
Not in our library10.1073/pnas.74.10.4624
92.
Dinarello C. A. Rosenwasser L. J. Wolff S. M. (1981 ). Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans. J. Immunol. 127 2517–2519.
Not in our library
93.
Dinarello C. A. Simon A. van der Meer J. W. (2012 ). Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11 633–652.
Not in our library10.1038/nrd3800
94.
Donath M. Y. Shoelson S. E. (2011 ). Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11 98–107.
Not in our library10.1038/nri2925
95.
Duewell P. Kono H. Rayner K. J. Sirois C. M. Vladimer G. Bauernfeind F. G. (2010 ). NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 1357–1361.
Not in our library10.1038/nature08938
96.
Dusser P. Kone-Paut I. (2017 ). IL-1 inhibition may have an important role in treating refractory Kawasaki disease. Front. Pharmacol. 8:163.
Not in our library10.3389/fphar.2017.00163
97.
Eisenberg S. P. Evans R. J. Arend W. P. Verderber E. Brewer M. T. Hannum C. H. (1990 ). Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343 341–346.
Not in our library10.1038/343341a0
98.
Eleftheriou D. Gerschman T. Sebire N. Woo P. Pilkington C. A. Brogan P. A. (2011 ). Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology 49 1505–1512.
Not in our library10.1093/rheumatology/keq122
99.
Emmenegger U. Reimers A. Frey U. Fux C. Bihl F. Semela D. (2002 ). Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med. Wkly. 132 230–236.
Not in our library10.4414/smw.2002.09941
100.
Emsley H. C. Smith C. J. Georgiou R. F. Vail A. Hopkins S. J. Rothwell N. J. (2005 ). A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry 76 1366–1372.
Not in our library10.1136/jnnp.2004.054882
101.
Eungdamrong J. Boyd K. P. Meehan S. A. Latkowski J. A. (2013 ). Muckle-wells treatment with anakinra. Dermatol. J. 19:20720.
Not in our library
102.
Everett B. M. Donath M. Y. Pradhan A. D. Thuren T. Pais P. Nicolau J. C. (2018 ). Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J. Am. Coll. Cardiol. 71 2392–2401.
Not in our library10.1016/j.jacc.2018.03.002
103.
Ferrero E. Corti A. Haroche J. Belloni D. Colombo B. Berti A. (2016 ). Plasma chromogranin a as a marker of cardiovascular involvement in Erdheim-Chester disease. Oncoimmunology 5:e1181244.
Not in our library10.1080/2162402x.2016.1181244
104.
Fitzgerald A. A. Leclercq S. A. Yan A. Homik J. E. Dinarello C. A. (2005 ). Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 52 1794–1803.
Not in our library10.1002/art.21061
105.
Fleischmann R. M. Schechtman J. Bennett R. Handel M. L. Burmester G. R. Tesser J. (2003 ). Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 48 927–934.
Not in our library10.1002/art.10870
106.
Fleischmann R. M. Tesser J. Schiff M. H. Schechtman J. Burmester G. R. Bennett R. (2006 ). Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65 1006–1012.
Not in our library10.1136/ard.2005.048371
107.
Franconieri F. Martin-Silva N. de Boysson H. Galateau-Salle F. Emile J. F. Bienvenu B. (2016 ). Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in erdheim-chester disease: towards the paradigm of combined targeting and immune therapies. Acta Oncol. 55 930–932.
Not in our library10.3109/0284186x.2015.1120885
108.
Galea J. Ogungbenro K. Hulme S. Greenhalgh A. Aarons L. Scarth S. (2011 ). Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J. Cereb. Blood Flow Metab. 31 439–447.
Not in our library10.1038/jcbfm.2010.103
109.
Galeotti C. Tran T.-A. Franchi-Abella S. Fabre M. Pariente D. Kone-Paut I. (2008 ). IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease. J. Pediatr. Hematol. Oncol. 30 920–924.
Not in our library10.1097/mph.0b013e31818ab31f
110.
Gamez-Gonzalez L. B. Moribe-Quintero I. Cisneros-Castolo M. Varela-Ortiz J. Munoz-Ramirez M. Garrido-Garcia M. (2018 ). Kawasaki disease shock syndrome; a unique and severe subtype of kawasaki disease. Pediatr. Int. 60 781–790.
Not in our library10.1111/ped.13614
111.
Gatti S. Beck J. Fantuzzi G. Bartfai T. Dinarello C. A. (2002 ). Effect of interleukin-18 on mouse core body temperature. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282 R702–R709.
Not in our library10.1152/ajpregu.00393.2001
112.
Gattorno M. Pelagatti M. A. Meini A. Obici L. Barcellona R. Federici S. (2008a ). Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58 1516–1520.
Not in our library10.1002/art.23475
113.
Gattorno M. Piccini A. Lasiglie D. Tassi S. Brisca G. Carta S. (2008b ). The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58 1505–1515.
Not in our library10.1002/art.23437
114.
Gattorno M. Tassi S. Carta S. Delfino L. Ferlito F. Pelagatti M. A. (2007 ). Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 56 3138–3148.
Not in our library10.1002/art.22842
115.
Genant H. K. Bresnihan B. Ng E. Robbins S. Newmark R. D. McCabe D. (2001 ). Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the secon 6 months of treatment for patients with rheumatoid arthritis. Ann. Rheum. Dis. 40(Suppl. 1):169.
Not in our library
116.
Gerard S. le Goff B. Maugars Y. Berthelot J. M. Malard O. (2007 ). Lasting remission of a Muckle-Wells syndrome with CIAS-1 mutation using half-dose anakinra. Joint Bone Spine 74:659.
Not in our library10.1016/j.jbspin.2007.01.032
117.
Gerfaud-Valentin M. Jamilloux Y. Iwaz J. Seve P. (2014 ). Adult-onset still’s disease. Autoimmun. Rev. 13 708–722.
Not in our library10.1016/j.autrev.2014.01.058
118.
Goldbach-Mansky R. (2011 ). Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr. Rheumatol. Rep. 13 123–131.
Not in our library10.1007/s11926-011-0165-y
119.
Goldbach-Mansky R. Dailey N. J. Canna S. W. Gelabert A. Jones J. Rubin B. I. (2006 ). Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 355 581–592.
Not in our library10.1056/nejmoa055137
120.
Granowitz E. V. Santos A. Poutsiaka D. D. Cannon J. G. Wilmore D. A. Wolff S. M. (1991 ). Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet 338 1423–1424.
Not in our library10.1016/0140-6736(91)92725-h
121.
Grayson P. C. Yazici Y. Merideth M. Sen H. N. Davis M. Novakovich E. (2017 ). Treatment of mucocutaneous manifestations in Behcet’s disease with anakinra: a pilot open-label study. Arthritis Res. Ther. 19:69.
Not in our library10.1186/s13075-017-1222-3
122.
Grom A. A. (2003 ). Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr. Opin. Rheumatol. 15 587–590.
Not in our library10.1097/00002281-200309000-00011
123.
Grom A. A. Mellins E. D. (2011 ). Macrophage activation syndrome: advances towards understanding pathogenesis. Curr. Opin. Rheumatol. 22 561–566.
Not in our library10.1097/01.bor.0000381996.69261.71
124.
Grom A. A. Villanueva J. Lee S. Goldmuntz E. A. Passo M. H. Filipovich A. (2003 ). Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr. 142 292–296.
Not in our library10.1067/mpd.2003.110
125.
Guarda G. Braun M. Staehli F. Tardivel A. Mattmann C. Forster I. (2011 ). Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34 213–223.
Not in our library10.1016/j.immuni.2011.02.006
126.
Gul A. Tugal-Tutkun I. Dinarello C. A. Reznikov L. Esen B. A. Mirza A. (2012 ). Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann. Rheum. Dis. 71 563–566.
Not in our library10.1136/annrheumdis-2011-155143
127.
Hannum C. H. Wilcox C. J. Arend W. P. Joslin F. G. Dripps D. J. Heimdal P. L. (1990 ). Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343 336–340.
Not in our library10.1038/343336a0
128.
Harrison S. R. McGonagle D. Nizam S. Jarrett S. van der Hilst J. McDermott M. F. (2016 ). Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight 1:e86336.
Not in our library10.1172/jci.insight.86336
129.
Haspolat S. Baysal Y. Duman O. Coskun M. Tosun O. Yegin O. (2005 ). Interleukin-1alpha, interleukin-1beta, and interleukin-1Ra polymorphisms in febrile seizures. J. Child Neurol. 20 565–568.
Not in our library10.1177/08830738050200070401
130.
Hawkins P. N. Lachmann H. J. McDermott M. F. (2003 ). Interleukin-1 receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348 2583–2584.
Not in our library10.1056/nejm200306193482523
131.
Hayashi M. Jin Y. Yorgov D. Santorico S. A. Hagman J. Ferrara T. M. (2016 ). Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A∗02:01 in vivo. Proc. Natl. Acad. Sci. U.S.A. 113 1357–1362.
Not in our library10.1073/pnas.1525001113
132.
Heida J. G. Moshe S. L. Pittman Q. J. (2009 ). The role of interleukin-1beta in febrile seizures. Brain Dev. 31 388–393.
Not in our library10.1016/j.braindev.2008.11.013
133.
Hedrich C. M. Fiebig B. Sallmann S. Bruck N. Hahn G. Roesler J. (2008 ). Good response to IL-1β blockade by anakinra in a 23-year-old CINCA/NOMID patient without mutations in the CIAS1 gene. Cytokine profiles and functional studies. Scand. J. Rheumatol. 37 385–389.
Not in our library10.1080/03009740801978889
134.
Helmy A. Guilfoyle M. R. Carpenter K. L. Pickard J. D. Menon D. K. Hutchinson P. J. (2014 ). Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J. Cereb. Blood Flow Metab. 34 845–851.
Not in our library10.1038/jcbfm.2014.23
135.
Hennig S. Bayegan K. Uffmann M. Thalhammer F. Winkler S. (2010 ). Pneumonia in a patient with familial mediterranean fever successfully treated with anakinra-case report and review. Rheumatol. Int. 32 1801–1804.
Not in our library10.1007/s00296-010-1429-y
136.
Herlin T. Fiirgaard B. Bjerre M. Kerndrup G. Hasle H. Bing X. (2013 ). Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann. Rheum. Dis. 72 410–413.
Not in our library10.1136/annrheumdis-2012-201818
137.
Hernandez-Rodriguez J. Segarra M. Vilardell C. Sanchez M. Garcia-Martinez A. Esteban M. J. (2004 ). Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 43 294–301.
Not in our library10.1093/rheumatology/keh058
138.
Hirsch L. J. Gaspard N. van Baalen A. Nabbout R. Demeret S. Loddenkemper T. (2018 ). Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 59 739–744.
Not in our library10.1111/epi.14016
139.
Hoffman H. M. Wanderer A. A. (2011 ). Inflammasome and IL-1beta-mediated disorders. Curr. Allergy Asthma Rep. 10 229–235.
Not in our library10.1007/s11882-010-0109-z
140.
Honda K. Ohga S. Takada H. Nomura A. Ohshima K. Kinukawa N. (2000 ). Neuron-specific enolase in hemophagocytic lymphohistiocytosis: a potential indicator for macrophage activation? Int. J. Hematol. 72 55–60.
Not in our library
141.
Hornung V. Bauernfeind F. Halle A. Samstad E. O. Kono H. Rock K. L. (2008 ). Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9 847–856.
Not in our library10.1038/ni.1631
142.
Hsiao J. L. Antaya R. J. Berger T. Maurer T. Shinkai K. Leslie K. S. (2011 ). Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch. Dermatol. 146 1265–1270.
Not in our library10.1001/archdermatol.2010.328
143.
Hsieh C. W. Chen Y. M. Lin C. C. Tang K. T. Chen H. H. Hung W. T. (2017 ). Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset still disease. J. Rheumatol. 44 1142–1150.
Not in our library10.3899/jrheum.161354
144.
Ikonomidis I. Lekakis J. P. Nikolaou M. Paraskevaidis I. Andreadou I. Kaplanoglou T. (2008 ). Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 117 2662–2669.
Not in our library10.1161/circulationaha.107.731877
145.
Ilowite N. Porras O. Reiff A. Rudge S. Punaro M. Martin A. (2009 ). Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin. Rheumatol. 28 129–137.
Not in our library10.1007/s10067-008-0995-9
146.
Imazio M. (2014 ). Idiopathic recurrent pericarditis as an immune-mediated disease: current insights into pathogenesis and emerging treatment options. Expert Rev. Clin. Immunol. 10 1487–1492.
Not in our library10.1586/1744666x.2014.965150
147.
Iurlo A. Dagna L. Cattaneo D. Orofino N. Bianchi P. Cavalli G. (2016 ). Erdheim-chester disease with multiorgan involvement, following polycythemia vera: a case report. Medicine 95:e3697.
Not in our library10.1097/md.0000000000003697
148.
Janka G. E. (2012 ). Familial and acquired hemophagocytic lymphohistiocytosis. Annu. Rev. Med. 63 233–246.
Not in our library10.1146/annurev-med-041610-134208
149.
Jeru I. (2011 ). Role of interleukin-1 in NLRP12-associated autoinflammatory disorders and resistance to anti–. (Interleukin)-1 therapy. Arthritis Rheum. 63 2142–2148.
Not in our library10.1002/art.30378
150.
Joosten L. A. Netea M. G. Fantuzzi G. Koenders M. I. Helsen M. M. Sparrer H. (2009 ). Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum. 60 3651–3662.
Not in our library10.1002/art.25006
151.
Joosten L. A. Netea M. G. Mylona E. Koenders M. I. Malireddi R. K. Oosting M. (2010 ). Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62 3237–3248.
Not in our library10.1002/art.27667
152.
Junge G. Mason J. Feist E. (2017 ). Adult onset Still’s disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin. Arthritis Rheum. 47 295–302.
Not in our library10.1016/j.semarthrit.2017.06.006
153.
Kamari Y. Werman-Venkert R. Shaish A. Werman A. Harari A. Gonen A. (2007 ). Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis 195 31–38.
Not in our library10.1016/j.atherosclerosis.2006.11.026
154.
Kanemoto K. Kawasaki J. Miyamoto T. Obayashi H. Nishimura M. (2000 ). Interleukin (IL)1beta, IL-1alpha, and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy. Ann. Neurol. 47 571–574.
Not in our library
155.
Kelly A. Ramanan A. V. (2008 ). A case of macrophage activation syndrome successfully treated with anakinra. Nat. Clin. Pract. Rheumatol. 4 615–620.
Not in our library10.1038/ncprheum0919
156.
Kelly C. Hamilton J. (2007 ). What kills patients with rheumatoid arthritis? Rheumatology 46 183–184.
Not in our library10.1093/rheumatology/kel332
157.
Kenney-Jung D. L. Vezzani A. Kahoud R. J. LaFrance-Corey R. G. Ho M. L. Muskardin T. W. (2016 ). Febrile infection-related epilepsy syndrome treated with anakinra. Ann. Neurol. 80 939–945.
Not in our library10.1002/ana.24806
158.
Killu A. M. Liang J. J. Jaffe A. S. (2013 ). Erdheim-chester disease with cardiac involvement successfully treated with anakinra. Int. J. Cardiol. 167 e115–e117.
Not in our library10.1016/j.ijcard.2013.04.057
159.
Kitley J. L. Lachmann H. J. Pinto A. Ginsberg L. (2010 ). Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology 74 1267–1270.
Not in our library10.1212/wnl.0b013e3181d9ed69
160.
Klein A. K. Horneff G. (2011 ). Improvement of sensoneurinal hearing loss in a patient with muckle-wells syndrome treated with anakinra. Klin. Padiatr. 222 266–268.
Not in our library10.1055/s-0029-1239527
161.
Kluger N. Gil-Bistes D. Guillot B. Bessis D. (2011 ). Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret(R)) in a case of refractory Sweet’s syndrome. Dermatology 222 123–127.
Not in our library10.1159/000326112
162.
Kone-Paut I. Cimaz R. Herberg J. Bates O. Carbasse A. Saulnier J. P. (2018 ). The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmun. Rev. 17 768–774.
Not in our library10.1016/j.autrev.2018.01.024
163.
Kuemmerle-Deschner J. B. Hachulla E. Cartwright R. Hawkins P. N. Tran T. A. Bader-Meunier B. (2011a ). Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 70 2095–2102.
Not in our library10.1136/ard.2011.152728
164.
Kuemmerle-Deschner J. B. Lohse P. Koetter I. Dannecker G. E. Reess F. Ummenhofer K. (2011b ). NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment. Arthritis Res. Ther. 13:R196.
Not in our library10.1186/ar3526
165.
Kuemmerle-Deschner J. B. Tyrrell P. N. Koetter I. Wittkowski H. Bialkowski A. Tzaribachev N. (2011c ). Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum. 63 840–849.
Not in our library10.1002/art.30149
166.
Kuemmerle-Deschner J. B. Wittkowski H. Tyrrell P. N. Koetter I. Lohse P. Ummenhofer K. (2013 ). Treatment of Muckle-wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res. Ther. 15:R64.
Not in our library10.1186/ar4237
167.
Kullenberg T. Lofqvist M. Leinonen M. Goldbach-Mansky R. Olivecrona H. (2016 ). Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology 55 1499–1506.
Not in our library10.1093/rheumatology/kew208
168.
Kumar N. Goyal J. Goel A. Shakoory B. Chatham W. (2014 ). Macrophage activation syndrome secondary to human monocytic ehrlichiosis. Indian J. Hematol. Blood Transfus. 30(Suppl. 1) 145–147.
Not in our library10.1007/s12288-013-0299-3
169.
Lachmann H. J. Kone-Paut I. Kuemmerle-Deschner J. B. Leslie K. S. Hachulla E. Quartier P. (2009 ). Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360 2416–2425.
Not in our library10.1056/nejmoa0810787
170.
Larroche C. Mouthon L. (2004 ). Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun. Rev. 3 69–75.
Not in our library10.1016/s1568-9972(03)00091-0
171.
Larsen C. M. Faulenbach M. Vaag A. Ehses J. A. Donath M. Y. Mandrup-Poulsen T. (2009 ). Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32 1663–1668.
Not in our library10.2337/dc09-0533
172.
Larsen C. M. Faulenbach M. Vaag A. Volund A. Ehses J. A. Seifert B. (2007 ). Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356 1517–1526.
Not in our library10.1056/nejmoa065213
173.
Lee J. K. Kim S. H. Lewis E. C. Azam T. Reznikov L. L. Dinarello C. A. (2004 ). Differences in signaling pathways by IL-1beta and IL-18. Proc. Natl. Acad. Sci. U.S.A. 101 8815–8820.
Not in our library10.1073/pnas.0402800101
174.
Lepore L. Paloni G. Caorsi R. Alessio M. Rigante D. Ruperto N. (2011 ). Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J. Pediatr. 157 310e1–315.e1.
Not in our library10.1016/j.jpeds.2010.02.040
175.
Leung C. C. Yu I. T. Chen W. (2012 ). Silicosis. Lancet 379 2008–2018.
Not in our library10.1016/s0140-6736(12)60235-9
176.
Libby P. Ridker P. M. Maseri A. (2002 ). Inflammation and atherosclerosis. Circulation 105 1135–1143.
Not in our library10.1161/hc0902.104353
177.
Lipsker D. Perrigouard C. Foubert A. Cribier B. (2010 ). Anakinra for difficult-to-treat neutrophilic panniculitis: IL-1 blockade as a promising treatment option for neutrophil-mediated inflammatory skin disease. Dermatology 220 264–267.
Not in our library10.1159/000280436
178.
Lomedico P. T. Gubler R. Hellmann C. P. Dukovich M. Giri J. G. Pan Y. E. (1984 ). Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 312 458–462.
Not in our library10.1038/312458a0
179.
Lopalco G. Rigante D. Giannini M. Galeazzi M. Lapadula G. Iannone F. (2016a ). Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clin. Exp. Rheumatol. 34 531–538.
Not in our library
180.
Lopalco G. Vitale A. Iannone F. Cantarini L. (2016b ). Anakinra long-term efficacy and safety in the management of Schnitzler’s syndrome and latent tuberculosis infection. Clin. Exp. Rheumatol. 34:353.
Not in our library
181.
Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease · 2013
No notice
182.
Ly K. H. Stirnemann J. Liozon E. Michel M. Fain O. Fauchais A. L. (2013 ). Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine 81 76–78.
Not in our library10.1016/j.jbspin.2013.06.004
183.
Maedler K. Sergeev P. Ris F. Oberholzer J. Joller-Jemelka H. I. Spinas G. A. (2002 ). Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110 851–860.
Not in our library10.1172/jci15318
184.
Maeno N. Takei S. Imanaka H. Yamamoto K. Kuriwaki K. Kawano Y. (2004 ). Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 50 1935–1938.
Not in our library10.1002/art.20268
185.
Marchi N. Fan Q. Ghosh C. Fazio V. Bertolini F. Betto G. (2009 ). Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol. Dis. 33 171–181.
Not in our library10.1016/j.nbd.2008.10.002
186.
Martinon F. Mayor A. Tschopp J. (2009 ). The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27 229–265.
Not in our library10.1146/annurev.immunol.021908.132715
187.
Marzano A. V. Ishak R. S. Saibeni S. Crosti C. Meroni P. L. Cugno M. (2013 ). Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and sweet’s syndrome: a comprehensive review and disease classification criteria. Clin. Rev. Allergy Immunol. 45 202–210.
Not in our library10.1007/s12016-012-8351-x
188.
Masters S. L. Dunne A. Subramanian S. L. Hull R. L. Tannahill G. M. Sharp F. A. (2010 ). Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat. Immunol. 11 897–904.
Not in our library10.1038/ni.1935
189.
Mazodier K. Marin V. Novick D. Farnarier C. Robitail S. Schleinitz N. (2005 ). Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106 3483–3489.
Not in our library10.1182/blood-2005-05-1980
190.
McDermott M. F. Aksentijevich I. Galon J. McDermott E. M. Ogunkolade B. W. Centola M. (1999 ). Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97 133–144.
Not in our library10.1016/s0092-8674(00)80721-7
191.
McGonagle D. Tan A. L. Madden J. Emery P. McDermott M. F. (2008 ). Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 58 631–633.
Not in our library10.1002/art.23119
192.
McGonagle D. Tan A. L. Shankaranarayana S. Madden J. Emery P. McDermott M. F. (2007 ). Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann. Rheum. Dis. 66 1683–1684.
Not in our library10.1136/ard.2007.073759
193.
Meinzer U. Quartier P. Alexandra J. F. Hentgen V. Retornaz F. Kone-Paut I. (2011 ). Interleukin-1 targeting drugs in familial mediterranean fever: a case series and a review of the literature. Semin. Arthritis Rheum. 41 265–271.
Not in our library10.1016/j.semarthrit.2010.11.003
194.
Mertens M. Singh J. A. (2009a ). Anakinra for rheumatoid arthritis. Cochrane Database Syst. Rev. 21:CD005121.
Not in our library10.1002/14651858.cd005121.pub3
195.
Mertens M. Singh J. A. (2009b ). Anakinra for rheumatoid arthritis: a systematic review. J. Rheumatol. 36 1118–1125.
Not in our library10.3899/jrheum.090074
196.
Miettunen P. M. Narendran A. Jayanthan A. Behrens E. M. Cron R. Q. (2012 ). Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology 50 417–419.
Not in our library10.1093/rheumatology/keq218
197.
Moran A. Bundy B. Becker D. J. DiMeglio L. A. Gitelman S. E. Goland R. (2013 ). Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381 1905–1915.
Not in our library10.1016/s0140-6736(13)60023-9
198.
Morton A. C. Rothman A. M. Greenwood J. P. Gunn J. Chase A. Clarke B. (2015 ). The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur. Heart J. 36 377–384.
Not in our library10.1093/eurheartj/ehu272
199.
Moser C. Pohl G. Haslinger I. Knapp S. Rowczenio D. Russel T. (2009 ). Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol. Dial. Transplant. 24 676–678.
Not in our library10.1093/ndt/gfn646
200.
Movva R. Brown S. B. Morris D. L. Figueredo V. M. (2013 ). Anakinra for myocarditis in juvenile idiopathic arthritis. Tex. Heart Inst. J. 40 623–625.
Not in our library
201.
Mulders-Manders C. M. Baas M. C. Molenaar F. M. Simon A. (2017 ). Peri- and postoperative treatment with the interleukin-1 receptor antagonist anakinra is safe in patients undergoing renal transplantation: case series and review of the literature. Front. Pharmacol. 8:342.
Not in our library10.3389/fphar.2017.00342
202.
Murphy P. A. Cebula T. A. Levin J. Windle B. E. (1981 ). Rabbit macrophages secrete two biochemically and immunologically distinct endogenous pyrogens. Infect. Immun. 34 177–183.
Not in our library10.1128/iai.34.1.177-183.1981
203.
Nakayama J. Arinami T. (2006 ). Molecular genetics of febrile seizures. Epilepsy Res. 70(Suppl. 1) S190–S198.
Not in our library10.1016/j.eplepsyres.2005.11.023
204.
Naumann L. Feist E. Natusch A. Langen S. Krause A. Buttgereit F. (2010 ). IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease. Ann. Rheum. Dis. 69 466–467.
Not in our library10.1136/ard.2009.108068
205.
Netea M. G. Balkwill F. Chonchol M. Cominelli F. Donath M. Y. Giamarellos-Bourboulis E. J. (2017 ). A guiding map for inflammation. Nat. Immunol. 18 826–831.
Not in our library10.1038/ni.3790
206.
Neven B. Marvillet I. Terrada C. Ferster A. Boddaert N. Couloignier V. (2011 ). Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 62 258–267.
Not in our library10.1002/art.25057
207.
Nold M. F. Nold-Petry C. A. Zepp J. A. Palmer B. E. Bufler P. Dinarello C. A. (2010 ). IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 11 1014–1022.
Not in our library10.1038/ni.1944
208.
Interleukin-1 Inhibition and Fatigue in Primary Sjögren's Syndrome – A Double Blind, Randomised Clinical Trial · 2012
No notice
209.
Novick D. Schwartsburd B. Pinkus R. Suissa D. Belzer I. Sthoeger Z. (2001 ). A novel IL-18BP ELISA shows elevated serum il-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14 334–342.
Not in our library10.1006/cyto.2001.0914
210.
Ogilvie A. C. Hack C. E. Wagstaff J. van Mierlo G. J. Erenberg A. J. Thomsen L. L. (1996 ). IL-1 beta does not cause neutrophil degranulation but does lead to IL- 6, IL-8, and nitrite/nitrate release when used in patients with cancer. J. Immunol. 156 389–394.
Not in our library
211.
Ogilvie E. M. Khan A. Hubank M. Kellam P. Woo P. (2007 ). Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 56 1954–1965.
Not in our library10.1002/art.22644
212.
Ogungbenro K. Hulme S. Rothwell N. Hopkins S. Tyrrell P. Galea J. (2016 ). Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist. J. Pharmacokinet. Pharmacodyn. 43 1–12.
Not in our library10.1007/s10928-015-9450-0
213.
Ozen S. Bilginer Y. Ayaz N. A. Calguneri M. (2011 ). Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J. Rheumatol. 38 516–518.
Not in our library10.3899/jrheum.100718
214.
The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease · 2018
Not checked
215.
Pascual V. Allantaz F. Arce E. Punaro M. Banchereau J. (2005 ). Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201 1479–1486.
Not in our library10.1084/jem.20050473
216.
Pathak S. Goldofsky E. Vivas E. X. Bonagura V. R. Vambutas A. (2011 ). IL-1beta is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J. Immunol. 186 1870–1879.
Not in our library10.4049/jimmunol.1002275
217.
Pazyar N. Feily A. Yaghoobi R. (2012 ). An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr. Clin. Pharmacol. 7 271–275.
Not in our library10.2174/157488412803305821
218.
IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus · 2017
No notice
219.
Picco P. Brisca G. Traverso F. Loy A. Gattorno M. Martini A. (2009 ). Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum. 60 264–268.
Not in our library10.1002/art.24174
220.
Pomerantz B. J. Reznikov L. L. Harken A. H. Dinarello C. A. (2001 ). Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc. Natl. Acad. Sci. U.S.A. 98 2871–2876.
Not in our library10.1073/pnas.041611398
221.
Prieur A. M. Kaufmann M. T. Griscelli C. Dayer J. M. (1987 ). Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 2 1240–1242.
Not in our library10.1016/s0140-6736(87)91854-x
222.
Primdahl J. Clausen J. Horslev-Petersen K. (2013 ). Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. Ann. Rheum. Dis. 72 1771–1776.
Not in our library10.1136/annrheumdis-2013-203682
223.
Punzi L. Gava A. Galozzi P. Sfriso P. (2011 ). Miscellaneous non-inflammatory musculoskeletal conditions blau syndrome. Best Pract. Res. Clin. Rheumatol. 25 703–714.
Not in our library10.1016/j.berh.2011.10.017
224.
Quartier P. Allantaz F. Cimaz R. Pillet P. Messiaen C. Bardin C. (2011 ). A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70 747–754.
Not in our library10.1136/ard.2010.134254
225.
Raffeiner B. Botsios C. Dinarello C. A. Ometto F. Punzi L. Ramonda R. (2011 ). Adult-onset still’s disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine 78 100–101.
Not in our library10.1016/j.jbspin.2010.09.014
226.
Rajasekaran S. Kruse K. Kovey K. Davis A. T. Hassan N. E. Ndika A. N. (2014 ). Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children∗. Pediatr. Crit. Care Med. 15 401–408.
Not in our library10.1097/pcc.0000000000000078
227.
Reddy S. Jia S. Geoffrey R. Lorier R. Suchi M. Broeckel U. (2009 ). An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 360 2438–2444.
Not in our library10.1056/nejmoa0809568
228.
Ridker P. M. Everett B. M. Thuren T. MacFadyen J. G. Chang W. H. Ballantyne C. (2017 ). Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377 1119–1131.
Not in our library10.1056/nejmoa1707914
229.
Ridker P. M. MacFadyen J. G. Everett B. M. Libby P. Thuren T. Glynn R. J. (2018 ). Relationship of c-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391 319–328.
Not in our library10.1016/s0140-6736(17)32814-3
230.
Rigante D. Ansuini V. Caldarelli M. Bertoni B. La Torraca I. Stabile A. (2006 ). Hydrocephalus in CINCA syndrome treated with anakinra. Childs Nerv. Syst. 22 334–337.
Not in our library10.1007/s00381-006-1280-3
231.
Rissanen A. Howard C. P. Botha J. Thuren T. (2012 ). Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes. Metab. 14 1088–1096.
Not in our library10.1111/j.1463-1326.2012.01637.x
232.
Robertson M. J. Mier J. W. Logan T. Atkins M. Koon H. Koch K. M. (2006 ). Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res. 12(14 Pt 1) 4265–4273.
Not in our library10.1158/1078-0432.ccr-06-0121
233.
Rosenwasser L. J. Dinarello C. A. Rosenthal A. S. (1979 ). Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J. Exp. Med. 150 709–714.
Not in our library10.1084/jem.150.3.709
234.
Ruiz Gomez A. Couce M. L. Garcia-Villoria J. Torres A. Bana Souto A. Yague J. (2012 ). Clinical, genetic, and therapeutic diversity in 2 patients with severe mevalonate kinase deficiency. Pediatrics 129 e535–e539.
Not in our library10.1542/peds.2010-2192
235.
Ruperto N. Quartier P. Wulffraat N. Woo P. Ravelli A. Mouy R. (2012 ). A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 64 557–567.
Not in our library10.1002/art.33342
236.
Ryan J. G. de Koning H. D. Beck L. A. Booty M. G. Kastner D. L. Simon A. (2008 ). IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J. Allergy Clin. Immunol. 121 260–262.
Not in our library10.1016/j.jaci.2007.09.021
237.
Rynne M. Maclean C. Bybee A. McDermott M. F. Emery P. (2006 ). Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann. Rheum. Dis. 65 533–534.
Not in our library10.1136/ard.2005.038091
238.
Sakran W. Shalev S. A. Sakran W. Shalev S. A. El-Shanti H. Uziel Y. (2013 ). Chronic recurrent multifocal osteomyelitis and deficiency of interleukin-1-receptor antagonist. Pediatr. Infect. Dis. J. 32:94.
Not in our library10.1097/inf.0b013e3182700cc1
239.
Schellevis M. A. Stoffels M. Hoppenreijs E. P. Bodar E. Simon A. van der Meer J. W. (2011 ). Variable expression and treatment of PAPA syndrome. Ann. Rheum. Dis. 70 1168–1170.
Not in our library10.1136/ard.2009.126185
240.
Schulert G. S. Grom A. A. (2015 ). Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu. Rev. Med. 66 145–159.
Not in our library10.1146/annurev-med-061813-012806
241.
Scott I. C. Vijay Hajela V. Hawkins P. N. Lachmann H. J. (2011 ). A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. J. Cardiol. Cases 4 e93–e97.
Not in our library10.1016/j.jccase.2011.07.003
242.
Seckinger P. Lowenthal J. W. Williamson K. Dayer J. M. MacDonald H. R. (1987 ). A urine inhibitor of interleukin 1 activity that blocks ligand binding. J. Immunol. 139 1546–1549.
Not in our library
243.
Serdaroglu G. Alpman A. Tosun A. Pehlivan S. Ozkinay F. Tekgul H. (2009 ). Febrile seizures: interleukin 1beta and interleukin-1 receptor antagonist polymorphisms. Pediatr. Neurol. 40 113–116.
Not in our library10.1016/j.pediatrneurol.2008.10.004
244.
Settas L. D. Tsimirikas G. Vosvotekas G. Triantafyllidou E. Nicolaides P. (2007 ). Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J. Clin. Rheumatol. 13 219–220.
Not in our library10.1097/rhu.0b013e31812e00a1
245.
Shakoory B. Carcillo J. A. Chatham W. W. Amdur R. L. Zhao H. Dinarello C. A. (2016 ). Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit. Care Med. 44 275–281.
Not in our library10.1097/ccm.0000000000001402
246.
Shukla N. Risen S. Erklauer J. Lai Y. C. Riviello J. Muscal E. (2018 ). Anakinra (IL-1 blockade) use in children with suspected fires: a single institution experience. Neurology 90:346.
Not in our library
247.
Sibley C. H. Plass N. Snow J. Wiggs E. A. Brewer C. C. King K. A. (2012 ). Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 64 2375–2386.
Not in our library10.1002/art.34409
248.
Simon A. Bodar E. J. van der Hilst J. C. H. Van der Meer J. W. Fiselier T. J. W. Cuppen M. P. J. M. (2004 ). Beneficial response to interleukin-1 receptor antagonist in TRAPS. Am. J. Med. 117 208–210.
Not in our library10.1016/j.amjmed.2004.02.039
249.
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Not checked
250.
Singh N. Hopkins S. J. Hulme S. Galea J. P. Hoadley M. Vail A. (2014 ). The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. J. Neuroinflammation 11:1.
Not in our library10.1186/1742-2094-11-1
251.
Sloan-Lancaster J. Abu-Raddad E. Polzer J. Miller J. W. Scherer J. C. De Gaetano A. (2013 ). Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care 36 2239–2246.
Not in our library10.2337/dc12-1835
252.
Solovic I. Sester M. Gomez-Reino J. J. Rieder H. L. Ehlers S. Milburn H. J. (2011 ). The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur. Respir. J. 36 1185–1206.
Not in our library10.1183/09031936.00028510
253.
Sonmez H. E. Demir S. Bilginer Y. Ozen S. (2018 ). Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin. Rheumatol. [Epub ahead of print].
Not in our library10.1007/s10067-018-4095-1
254.
Sparsa L. Afif N. Goetz J. Sordet C. Chatelus E. Lipsker D. (2012 ). Jessner-Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus? Rheumatol. Int. 31 255–258.
Not in our library10.1007/s00296-009-1169-z
255.
Stankovic Stojanovic K. Delmas Y. Torres P. U. Peltier J. Pelle G. Jeru I. (2012 ). Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial mediterranean fever complicated with amyloidosis and renal failure. Nephrol. Dial. Transplant. 27 1898–1901.
Not in our library10.1093/ndt/gfr528
256.
Stew B. T. Fishpool S. J. Owens D. Quine S. (2013 ). Muckle-Wells syndrome: a treatable cause of congenital sensorineural hearing loss. B-ENT 9 161–163.
Not in our library
257.
Stienstra R. Joosten L. A. Koenen T. van Tits B. van Diepen J. A. van den Berg S. A. (2011 ). The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12 593–605.
Not in our library10.1016/j.cmet.2010.11.011
258.
Stoffels M. Simon A. (2011 ). Hyper-IgD syndrome or mevalonate kinase deficiency. Curr. Opin. Rheumatol. 23 419–423.
Not in our library10.1097/bor.0b013e328349c3b1
259.
Stojanov S. Lapidus S. Chitkara P. Feder H. Salazar J. C. Fleisher T. A. (2011 ). Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc. Natl. Acad. Sci. U.S.A. 108 7148–7153.
Not in our library10.1073/pnas.1103681108
260.
Stuyt R. J. Netea M. G. Verschueren I. Dinarello C. A. Kullberg B. J. van der Meer J. W. (2005 ). Interleukin-18 does not modulate the acute-phase response. J. Endotoxin. Res. 11 85–88.
Not in our library10.1179/096805105x35170
261.
Sumegi J. Barnes M. G. Nestheide S. V. Molleran-Lee S. Villanueva J. Zhang K. (2011 ). Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood 117 e151–e160.
Not in our library10.1182/blood-2010-08-300046
262.
Tan Z. S. Beiser A. S. Vasan R. S. Roubenoff R. Dinarello C. A. Harris T. B. (2007 ). Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68 1902–1908.
Not in our library10.1212/01.wnl.0000263217.36439.da
263.
Tilg H. Mier J. W. Vogel W. Aulitzky W. E. Wiedermann C. J. Vannier E. (1993 ). Induction of circulating IL-1 receptor antagonist by IFN treatment. J. Immunol. 150 4687–4692.
Not in our library
264.
Toldo S. Mezzaroma E. O’Brien L. Marchetti C. Seropian I. M. Voelkel N. F. (2014 ). Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am. J. Physiol. Heart Circ. Physiol. 306 H1025–H1031.
Not in our library10.1152/ajpheart.00795.2013
265.
Toldo S. Mezzaroma E. Van Tassell B. W. Farkas D. Marchetti C. Voelkel N. F. (2013 ). Interleukin-1beta blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp. Physiol. 98 734–745.
Not in our library10.1113/expphysiol.2012.069831
266.
Tomelleri A. Cavalli G. De Luca G. Campochiaro C. D’Aliberti T. Tresoldi M. (2018 ). Treating heart inflammation with interleukin-1 blockade in a case of erdheim-chester disease. Front. Immunol. 9:1233.
Not in our library10.3389/fimmu.2018.01233
267.
Tzanetakou V. Kanni T. Giatrakou S. Katoulis A. Papadavid E. Netea M. G. (2016 ). Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 152 52–59.
Not in our library10.1001/jamadermatol.2015.3903
268.
Uludag I. F. Bilgin S. Zorlu Y. Tuna G. Kirkali G. (2013 ). Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures. Seizure 22 457–461.
Not in our library10.1016/j.seizure.2013.03.004
269.
Uludag I. F. Duksal T. Tiftikcioglu B. I. Zorlu Y. Ozkaya F. Kirkali G. (2015 ). IL-1beta, IL-6 and IL1Ra levels in temporal lobe epilepsy. Seizure 26 22–25.
Not in our library10.1016/j.seizure.2015.01.009
270.
Vambutas A. Lesser M. Mullooly V. Pathak S. Zahtz G. Rosen L. (2014 ). Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. J. Clin. Invest. 124 4115–4122.
Not in our library10.1172/jci76503
271.
van Asseldonk E. J. Stienstra R. Koenen T. B. Joosten L. A. Netea M. G. Tack C. J. (2011 ). Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 96 2119–2126.
Not in our library10.1210/jc.2010-2992
272.
New Insights in the Immunobiology of IL-1 Family Members · 2013
No notice
273.
van de Veerdonk F. L. Netea M. G. Dinarello C. A. van der Meer J. W. (2011 ). Anakinra for the inflammatory complications of chronic granulomatous disease. Neth. J. Med. 69:95.
Not in our library
274.
van der Ven A. J. Netea M. G. van der Meer J. W. de Mast Q. (2015 ). Ebola virus disease has features of hemophagocytic lymphohistiocytosis syndrome. Front. Med. 2:4.
Not in our library10.3389/fmed.2015.00004
275.
Van Tassell B. W. Abouzaki N. A. Oddi Erdle C. Carbone S. Trankle C. R. Melchior R. D. (2016 ). Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study. J. Cardiovasc. Pharmacol. 67 544–551.
Not in our library10.1097/fjc.0000000000000378
276.
Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure · 2012
No notice
277.
Van Tassell B. W. Canada J. Carbone S. Trankle C. Buckley L. Oddi Erdle C. (2017 ). Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART. Circ. Heart Fail. 10:e004373.
Not in our library10.1161/circheartfailure.117.004373
278.
Vastert S. J. de Jager W. Noordman B. J. Holzinger D. Kuis W. Prakken B. J. (2014 ). Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 66 1034–1043.
Not in our library10.1002/art.38296
279.
Vezzani A. Maroso M. Balosso S. Sanchez M. A. Bartfai T. (2011 ). IL-1 receptor/toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav. Immun. 25 1281–1289.
Not in our library10.1016/j.bbi.2011.03.018
280.
Vitale A. Insalaco A. Sfriso P. Lopalco G. Emmi G. Cattalini M. (2016 ). A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front. Pharmacol. 7:380.
Not in our library10.3389/fphar.2016.00380
281.
Wada T. Muraoka M. Yokoyama T. Toma T. Kanegane H. Yachie A. (2013 ). Cytokine profiles in children with primary epstein-barr virus infection. Pediatr. Blood Cancer 60 E46–E48.
Not in our library10.1002/pbc.24480
282.
Waghmare S. Valecka B. Cairns A. P. (2015 ). A severe case of adult onset Stills isease with myopericarditis, resistant to treatment with tocilizumab but responsive to anakinra. Ulster Med. J. 84 130–132.
Not in our library
283.
Wendling D. Prati C. Aubin F. (2012 ). Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann. Rheum. Dis. 71 1098–1100.
Not in our library10.1136/annrheumdis-2011-200743
284.
Zarchi K. Dufour D. N. Jemec G. B. (2013 ). Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol. 149 1192–1194.
Not in our library10.1001/jamadermatol.2013.5377
285.
Zufferey P. So A. (2013 ). A pilot study of IL-1 inhibition in acute calcific periarthritis of the shoulder. Ann. Rheum. Dis. 72 465–467.
Not in our library10.1136/annrheumdis-2012-202380

Cited by papers we hold 9

Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond · 2021
No notice
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion · 2021
No notice
Immunopathogenesis and treatment of cytokine storm in COVID-19 · 2021
No notice
Alternative Pathways of IL-1 Activation, and Its Role in Health and Disease · 2020
No notice
Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis—A Critical Review of Its Pathogenesis and Treatment · 2020
No notice
Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19 · 2020
Corrected
Focus on the Role of NLRP3 Inflammasome in Diseases · 2020
No notice
Cytokines in CAR T Cell–Associated Neurotoxicity · 2020
No notice
Biology of IL-36 Signaling and Its Role in Systemic Inflammatory Diseases · 2019
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.